Assessing the Impact of Chemotherapy Education on Practice Change for Error Prevention: A Program Evaluation by Wyant, Tracy
Running head: ASSESSING THE IMPACT OF CHEMOTHERAPY EDUCATION 1 
 
 
 
 
Assessing the Impact of Chemotherapy Education on Practice Change for Error Prevention:  
A Program Evaluation 
 
Doctor of Nursing Practice (DNP) Final Project 
 
Presented in Partial Fulfillment of the Requirements for the Doctor of Nursing Practice Degree 
in the Graduate School of the Ohio State University 
 
By 
Tracy C. Wyant, MSN, RN-BC, AOCN®, CHPN®, CPPS 
 
Graduate Program in Nursing 
The Ohio State University 
2017 
 
DNP Project Committee: 
Kristine Browning, PhD, ANP-BC, FAANP, Advisor 
Dori Klemanski, DNP, CNP 
Janine Overcash, PhD, GNP-BC, FAANP 
ASSESSING THE IMPACT OF CHEMOTHERAPY EDUCATION 2 
Abstract 
Antineoplastic regimens are complex, with inherent toxicity and narrow therapeutic 
indices that may result in life-threatening patient harm should an error occur. Chemotherapy 
nurses need to have specialized knowledge and competence in error prevention and recognition. 
Additionally, workplace culture, leadership, and policies and procedures must provide support 
for safe chemotherapy care. This project assessed how completion of a comprehensive 
chemotherapy course may impact individual and organizational error prevention strategies. 
Fifteen error preventive nursing behaviors were identified in practice guidelines and standards. 
These critical behaviors and the organizational processes to support them were addressed in a 
descriptive, cross-sectional survey that utilized retrospective, self-reported data from 334 
registered nurses who completed the course between October 2015 and March 2016. Course 
content impacted practice with up to 27% of respondents reporting either increased awareness of 
the need to perform a specific behavior, or that they had initiated change in a specific behavior. 
Overall, the two nursing behaviors impacted most related to verifying drug-specific dose limits 
and using generic drug names. Nurses holding professional oncology certification reported a 
lesser impact on nine of the practice behaviors than non-certified nurses. Organizationally, at 
least 30% started discussions with colleagues related to policies and procedures. More than 60% 
encountered at least one barrier to individual and organizational change. This program evaluation 
was an initial step in exploring knowledge application to practice through behaviors that promote 
chemotherapy error prevention. Recommendations for practice are: 1) provide comprehensive 
chemotherapy education for oncology nurses, 2) integrate practice guidelines and standards, 3) 
assess practice change needs related to critical nursing behaviors, 4) implement organizational 
processes to support practice change, and 5) prioritize a culture of safety.   
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Assessing the Impact of Chemotherapy Education on Practice Change for Error Prevention:  
A Program Evaluation 
Section One 
Introduction of the Problem 
Medication Errors 
The Institute of Medicine (IOM), now the National Academy of Medicine (NAM), has 
issued a series of reports that focus on the prevalence and effects of medical errors on patient 
outcomes. These reports have heightened public awareness of medical errors, impacted health 
care policy and health system accreditation, affected reimbursement outcome reporting criteria, 
provided strategies for error recognition and response, and urged error elimination through 
system safety initiatives and individual practice change (IOM, 1999a; IOM, 1999b; IOM, 2001; 
IOM, 2003; IOM, 2004; IOM, 2006; IOM, 2013). One key component of the IOM reports and 
recommendations is the prevention of medication errors. To provide clarity, the definition of a 
medication error is, “any preventable event that may cause or lead to inappropriate medication 
use or patient harm while the medication is in the control of the healthcare professional, patient, 
or consumer” (NCCMERP, 2016, para. 1). Experts estimate preventable medication errors 
account for more than 7,000 deaths and harm another 1,500,000 patients per year in the United 
States (U.S.) (Ehlert & Rough, 2013; IOM, 1999b; IOM, 2006).  
Chemotherapy Errors 
 Of significance to the oncology environment is the IOM (1999a) notation that error 
prevention is “particularly important for cancer chemotherapy” (p. 164). A collaboratively 
developed definition of chemotherapy is used for this project and refers to “any antineoplastic 
agents used to treat cancer” (Neuss et al., 2013, p. 226) with the exception of hormonal agents. 
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Practice guidelines and standards, along with health policy recommendations, address drug-
specific and patient-specific concerns that may interfere with safe chemotherapy prescribing, 
admixture, and administration (IOM, 1999a; Neuss et al., 2013; Polovich, Olsen, & LeFebvre, 
2014; Shulman, 2015). Patient-specific factors such as advancing age and comorbidities may 
complicate chemotherapy dosing due to organ dysfunction, and impact treatment effects and 
response. Cancer disparities including access to care and treatment costs are known to impact 
patient safety when undergoing treatment for cancer (ASCO, 2016; Edwards & Bencheikh, 2016; 
IOM, 2013). Lastly, IOM reports have contributed to risk evaluation and mitigation strategies 
(REMS) for oncologic supportive care agents (Damron & Phillips, 2015).  
Chemotherapy Error Prevention 
 Safe chemotherapy care involves organizational and individual accountability and 
collaboration between ordering providers, pharmacists, and nurses (Neuss et al., 2013; Shulman, 
2015). Healthcare organizations need processes and tools in place to enable appropriate 
treatment verification and safe administration (Neuss et al., 2013; Shulman, 2015). Clinical 
guidelines and standards include safe chemotherapy practice recommendations for organizational 
policy and procedure development (Neuss et al., 2013; Polovich et al., 2014; Shulman, 2015).   
 The actual incidence of adoption and extent of chemotherapy error prevention strategy 
integration are unknown, and errors may still occur within any phase of treatment planning and 
medication administration (Bruce, 2013; Nelson, Moore, Grasso, Barbarotta, & Fischer, 2014; 
Polovich, Olsen, & LeFebvre, 2014; Shulman, 2015). Choi et al. (2016) also report most 
medication errors occur or are reported during medication administration. Specific to 
chemotherapy, the primary type of reported errors are those involving dosing. Although many of 
these events do not reach the patient, they are often linked to the nurse as a key contributor in 
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preventing harm to patients through error recognition (Polovich, 2015; Polovich et al., 2014; 
Shulman, 2015; Walsh, Dodd, & Seetharaman, 2009). The foremost proactive strategy for 
chemotherapy error prevention during pretreatment and treatment administration phases is 
noted within practice guidelines and standards as comprehensive education and subsequent 
development of chemotherapy competency for nurses. The recommendation is for initial and 
ongoing didactic training followed by skill assessment that emphasizes the components of safe 
chemotherapy administration specific to the context of the care setting (Neuss et al., 2013; 
Polovich, 2015; Polovich et al., 2014).  
Chemotherapy Education for Nurses 
 The dynamic shift in cancer treatment settings, increasing complexity of treatment 
regimens, and antineoplastics being administered for non-oncology conditions lead to increasing 
numbers of nurses needing specialized knowledge to administer hazardous agents and to care for 
individuals experiencing their harsh effects. Educational interventions aimed at developing 
chemotherapy-competent nurses enhance the safety and quality of cancer nursing practice. A 
growing demand exists for chemotherapy nurses to provide safe and competent care to improve 
the quality outcomes of those with a cancer diagnosis (IOM, 2013). Chemotherapy care requires 
effective training, critical behavior and skill attainment, and clinical competence as the 
fundamental bases for safe administration of chemotherapy (Polovich et al., 2014).  
 Chemotherapy education through the Oncology Nursing Society. As a professional 
association of more than 39,000 members, the Oncology Nursing Society (ONS) provides 
evidence-based educational programs and advocates for the nursing profession and people with 
cancer through efforts that address safe care, improve quality of life, and focus on patient 
outcomes (ONS, 2017a). For more than 15 years, a nationally standardized and comprehensive 
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chemotherapy course has been offered by ONS. Starting as a live presentation offered by trainers 
across the U.S. in 1999, the program has evolved into an online certificate course and is a shared 
initiative developed by ONS and the Oncology Nursing Certification Corporation (ONCC). The 
course is designed for nurses who have been providing chemotherapy care for more than one 
year and administer it at least once a month. The purpose of the course is to “prepare and 
reinforce critical information for safe administration” of chemotherapy (ONS, 2016b, para. 3). 
Although error prevention strategies are fragmented within course content and the accompanying 
e-book, the program included a significant amount of content pertaining to safe chemotherapy 
care, including steps to mitigate errors and adverse events during pretreatment and treatment 
administration nursing tasks. Course and e-book content are inclusive of the critical role of 
vigilant nursing behaviors, and the need for underlying organizational policies and procedures 
that support those nursing behaviors. At the time this project was planned, the course included 
discussion forums that were facilitated by nurse experts in chemotherapy administration. The 
error prevention tasks and supporting processes discussed in the course comply with the ONS 
Chemotherapy and Biotherapy Guidelines and Recommendations for Practice and with the 
interprofessional practice standards collaboratively developed and endorsed by ONS and the 
American Society for Clinical Oncology (ASCO) which is the foremost professional association 
for practicing oncologist physicians (Neuss et al., 2013; ONS, 2015; Polovich et al., 2014).  
 ONS/ONCC chemotherapy program evaluation. At the time this project was 
conducted, the required elements of the ONS/ONCC course included submission of four 
discussion postings with facilitator feedback and a score of at least 80% on a multiple choice 
post-test to measure immediate knowledge retention. A general post-program evaluation 
determines the learner’s reaction to the educational program goals and process, and one 
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evaluation question asks participants whether or not they intend to change behaviors by applying 
course content to practice (ONS, 2016b). However, there is no further evaluation of the nurse 
to assesses if practice change has occurred through the application of the knowledge gained 
from the course into practice, as there is no further follow-up communication with the course 
participants.  
Practice Change and Compliance to Guidelines and Standards 
Practice change occurs as a result of triggered events, sometimes following a negative 
critical incident, due to knowledge gained from an educational intervention, or when practice 
guidelines and standards are consulted (Weber & Sidorov, 2014). Guidelines and standards 
compile and translate high level evidence into concise best practice statements (Weber & 
Sidoroy, 2014). For this project, error prevention strategies of focus were those recommended in 
the ONS guidelines (Polovich et al., 2014) and the ASCO/ONS practice standards (Neuss et al., 
2013). Of note, the 2013 version of the ASCO/ONS standards was used due to the participants 
taking the course prior to the release of the 2016 version (Neuss et al., 2013; Neuss et al., 2016).  
The desire was to learn how nurses who have successfully completed the ONS/ONCC 
course perceived the need to change practice to better comply with chemotherapy error 
prevention recommendations, and whether or not behaviors that impact error prevention were 
initiated within six months of course completion. The interval of six months was chosen since a 
general estimate of time from educational intervention to practice change is a minimum of six 
months, and up to two years (Weber & Sidorov, 2014; Porter-O’Grady & Malloch, 2015).  
To further demonstrate the importance of this project, email and telephone inquiries to 
the ONS staff from nurses who have completed the course often request clarification and 
evidence in an effort to advocate and support the need for enhancing their personal and 
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workplace processes for safe chemotherapy care. This may indicate practice change was being 
attempted and initiated due to program content, both at the individual nursing level and at the 
unit and organizational levels. Therefore, a need has been identified for measuring the 
effectiveness of the ONS/ONCC chemotherapy education program on impacting patient safety 
through integration of error prevention strategies at the individual and organizational levels.  
Barriers to Practice Change 
 While the need to identify the impact of education on error prevention strategies was the 
priority of this project, exploring perceived barriers to practice change was also desired. A 
published literature review comprised of eleven articles revealed limited knowledge about how 
the personal and professional aspects of nursing leadership, collaboration, and empowerment 
may impact patient safety (Richardson & Storr, 2010). The authors highlighted that nurses are 
the ideal drivers of quality and safety “because of their unique proximity to patients” 
(Richardson & Storr, 2010, p. 12). In addition to multiple personal factors, such as self-
confidence, the context of care and working environment have been found to influence the safety 
of medication administration. These include proactive versus reactive response to errors, trust in 
leadership, manager passivity, and inadequate training, guidance, and error reporting (Farag, 
Tullai-McGuinness, Anthony, & Burant, 2017; Fyhr, Ternoy, & Ek, 2015).  
Purpose of the Project 
The purpose of this project was to assess the impact of knowledge attained from a 
comprehensive chemotherapy course on individual nursing behaviors and organizational 
processes that are compliant with evidence-based chemotherapy error prevention strategies. A 
survey was conducted that reflects course content specific to chemotherapy error prevention at 
the individual and organizational levels. The survey addressed the course participants’ perceived 
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need for change and efforts to initiate change that improved compliance with chemotherapy error 
prevention strategies within practice guidelines and standards.  
Data was collected from a subset of registered nurses who successfully completed the 
ONS/ONCC Chemotherapy and Biotherapy Certificate course between October 1, 2015, and 
March 31, 2016. The setting for this project was the Education and Research Departments within 
the ONS national office in Pittsburgh, Pennsylvania.  
An observational design guided the project consisting of a descriptive cross-sectional 
survey that utilizes retrospective, self-reported data obtained through a web-based questionnaire. 
Survey content was developed based on fifteen recommended individual critical behaviors and 
their supporting organizational processes for chemotherapy error prevention interspersed in 
various components of the ONS Chemotherapy and Biotherapy Guidelines and 
Recommendations for Practice (Polovich et al., 2014) and the ASCO/ONS Chemotherapy 
Administration Safety Standards (Neuss et al., 2013).  
Statement of the Clinical Practice Problem 
The use of the Population-Intervention-Comparison-Outcome-Time (PICOT) clinical 
question format assisted in gaining the most relevant evidence for this project (Fineout-Overholt 
& Stillwell, 2015). The PICOT problem statement was: In nurses who have completed a 
comprehensive chemotherapy education program, was practice change to increase compliance 
with evidence-based chemotherapy error prevention strategies initiated within six months?  
Summary of Evidence from the Literature  
Literature Search Method 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
checklist was used to critically appraise the literature following an exhaustive literature search 
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(Moher, Liberati, Tetzlaff, & Altman, 2009; PRISMA Group, 2009). Three databases were 
accessed through the Ohio State University (OSU) Health Sciences Library (HSL), 
including PubMed, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), and Cochrane Library. Other sources include the ONS publications database, 
UptoDate, Researchgate, and the National Guidelines Clearinghouse. No meaningful limits were 
placed on the search processes. All data about the incidence of chemotherapy errors and the 
impact of strategies to minimize chemotherapy errors were desired. The search process involved 
specifically seeking information about the implementation of medication error prevention 
strategies and intervention outcomes. The most appropriate strategies and outcomes were those 
supporting the integration of chemotherapy education, policies, procedures, protocols, and error 
prevention behaviors as strategies to improve chemotherapy dosing and administration safety.   
Synthesis of the Evidence 
Tables of Evidence 
 Appendix A includes four tables synthesizing the evidence from the exhaustive literature 
search. Table A1 is a synthesis of studies to determine the incidence of chemotherapy errors. 
Table A2 shows the evaluation and synthesis of high level relevant expert committee reports, 
clinical guidelines, and practice standards that integrate evidence, expertise, and patient-specific 
content. Most encompassed social, ethical, and environmental determinants of cancer care to 
develop best practice considerations for chemotherapy settings. Included in the synthesis were 
nine expert reports with systematic reviews, and seven practice guidelines and standards 
resources. Table A3 provides an evaluation and synthesis of additional supporting literature 
related to medication and chemotherapy errors, including four systematic reviews, four direct 
observational studies, four literature reviews, and 20 descriptive studies including case reports, 
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quality improvement (QI) initiatives, retrospective and prospective record reviews, and 
exploratory surveys. The tables describe how the studies address factors influencing 
chemotherapy errors, and the recommendations for error preventive structures, processes, and 
behaviors. Details within Tables A2 and A3 also include the strength and quality of each piece of 
evidence, and the feasibility of including the evidence to support this project. 
 Table A4 is a synthesis of best practice recommendations for chemotherapy error 
prevention, recognition, and reporting at the system, unit, and individual levels compiled from 
many of the evidence sources in Tables A1, A2, and A3. Additionally, Appendix B includes 
Figure B1, showing an evidence-based root cause analysis of chemotherapy errors at the system, 
unit, and individual levels utilizing an Ishikawa (fishbone) diagram also compiled from sources 
of evidence in Tables A1, A2, and A3.  
Critical Appraisal of the Evidence 
 Critical appraisal of the evidence presented in Tables A1, A2, A3, A4, and in Figure B1 
assisted in validating the potential impact of this project. Firstly, detailed analysis demonstrated 
the great risk for harm should a chemotherapy error occur and the essentially unknown incidence 
of chemotherapy errors. Secondly, the literature review provided insight into the causes of 
chemotherapy errors, interprofessional accountability for error prevention, and recommended 
individual and organizational strategies aiming to mitigate chemotherapy errors. Critical 
appraisal of the evidence revealed two key needs: 1) chemotherapy error prevention education 
for nurses, and 2) evaluation of change in practice behaviors and underlying organizational 
processes to support the nurses’ role in preventing, recognizing, and reporting errors.    
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Chemotherapy and the Risk for Harm 
 Patient safety risks due to chemotherapy administration errors have been well 
documented in the literature. Many systemic agents used to treat cancer have narrow therapeutic 
indices combined with adverse effects leading to organ toxicity, thereby creating great risk for 
patient harm should a dosing error be unrecognized prior to administration (ASHP, 2015; Ehlert 
& Rough, 2013; Gandhi et al., 2005; IOM, 1999b; IOM, 2013; JC, 2005; Keers, et al., 2013; 
Neuss et al., 2013; Polovich, 2015; Ranchon et al., 2012; Schwappach & Wernli, 2010). The 
multilevel involvement of staff within organizations combined with the complexity of therapy 
regimens and essential dose calculations pose significant challenges in cancer treatment planning 
and administration.  Additionally, care may be fragmented due to poor communication and non-
integrated medical records between oncology and primary care providers (Shulman, 2015).  
Errors that reach the patient may result in poor outcomes and decreased quality of life for 
the patient, multiple ethical and legal ramifications for the healthcare organizations, and 
detrimental financial effects for both the patient and healthcare organization (ASHP, 2015; IOM, 
1999b; IOM, 2013; JC, 2005; JC, 2016; Keers, et al., 2013; Polovich, 2015; Ranchon et al., 
2012; Shulman, 2015). One overdosage miscalculation may lead to unplanned toxicity or even 
death. An under-dosing error may lead to reduced treatment efficacy and response, possibly 
impacting the chance for disease remission or cure (Shulman, 2015). However, many errors go 
completely unnoticed; some may become apparent if the severity of toxicities is unexpected, or if 
suboptimal treatment outcomes are recognized (Shulman, 2015).  
The risk for potentially devastating errors increases in multidrug regimens that are rapidly 
becoming standard of care, and necessitate the need for critical nursing behaviors with policies 
and procedures in place to reduce the risk for errors (ASHP, 2015; Baldwin & Rodriguez, 2016; 
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Ehlert & Rough, 2013; Ford et al., 2006; Gandhi et al., 2005; Harris & Northfelt, 2005; IOM, 
1999a; IOM, 1999b; IOM, 2013; JC, 2005; JC, 2016; Neuss et al., 2013; Polovich, 2015; 
Polovich et al., 2014; Ranchon et al., 2012; Schwappach & Wernli, 2010). While electronic 
health records and computerized ordering systems help to standardize processes, they often are 
not integrated between care settings, and fail to eliminate human error (Amato et al., 2016; 
Shulman, 2015).   
Chemotherapy Error Reporting 
Within the oncology environment, the American Society for Radiation Oncology 
(ASTRO) has initiated the creation of a national medical error reporting system. The program 
focuses “on improving patient safety and reducing the chances of medical errors during radiation 
therapy treatments” (ASTRO, 2016, para. 2). Pharmacovigilance through chemotherapy error 
reporting is not advancing as quickly, although the national adoption of systematic transparency 
and reporting metrics in error reporting is one recommendation of experts. Process measurement 
that includes safety-related variables is being realized as necessary in many oncology settings. 
However, while some organizations maintain voluntary, anonymous error reporting systems, 
there is no widely accepted method for chemotherapy error reporting (ASCO, 2016; Edwards & 
Bencheikh, 2016; IOM, 2013; Lennes et al., 2016; Shulman, 2015).  
Experts suggest the utility of process measures is higher when performance comparisons 
can be made. Furthermore, this type of benchmarking may be achievable through the support of 
professional associations and accrediting bodies to mitigate risks and accelerate patient safety 
outcomes (Lennes et al., 2016; Shulman, 2015). The Quality Oncology Practice Initiative 
(QOPI®) is a registry offered by the American Society of Clinical Oncology (ASCO) that 
indirectly includes error prevention strategies within its quality measures (ASCO, 2017). 
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Similarly, the Oncology Quality Clinical Data Registry (QCDR) offered by ONS includes 
measures to identify clinical care gaps that may lead to increased focus on error recognition and 
reporting (ONS, 2017b). Adherence to guidelines and standards is a component of the registries. 
However, appropriate dosing within chemotherapeutic regimens is not assessed, and electronic 
records are not linked to assist with dosing accuracy (Blayney et al., 2014; Shulman, 2015).  
Chemotherapy Error Incidence 
In a retrospective case-controlled study, Choi et al (2016) reviewed more than 57,000 
medical records finding that “medication errors occurred at a rate of 0.8 per 100 admissions, or 
1.6 per 1000 patient days” (p. 428) with significant financial impact regardless of patient harm. 
Specific to cancer treatments, the evidence presented in Table A1 reveals great variability in 
reported rates of chemotherapy errors. With the exact incidence and impact unknown, 
benchmarking is nearly impossible. While the literature suggests varying incidence rates, some 
errors are not discoverable due to lack of ongoing monitoring of treatment ordering, preparation, 
and administration (Neuss et al., 2013; Neuss et al., 2016; Ranchon et al., 2011).  
One study by Ford, Killebrew, Fugitt, Jacobsen, and Prystas (2006) suggests oncolytic 
errors account for up to 15.6% of all drug events. Data indicate between 0.3% and 6% of 
chemotherapy orders contain some type of error (see Table A1) (Baldwin & Rodriguez, 2016; 
Schwappach & Wernli, 2010). Error incidence is higher in regimens with more than three drugs 
or with dose modifications (Ranchon et al., 2012; Shulman, 2015). 
Despite the availability of preventive error management guidelines and standards (see 
Tables A2 and A3), errors are often unrecognized or under-reported. Most are prescriptive or 
documentation errors recognized before reaching the patient, yet many reported errors are 
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discovered during critical nursing tasks before and during treatment administration (Polovich, 
2015; Polovich et al., 2014; Walsh, Dodd, & Seetharaman, 2009; White et al., 2010).  
Chemotherapy Error Types and Causes  
Chemotherapy errors can be categorized based error type or factors influencing the error.  
Types of errors. Types of errors include incorrect drug, dose, route, patient, and day or 
timing, as well as lack of communicating a change in dose or protocol, and failure to document 
assessment or laboratory findings that result in missing an important consideration that should 
have delayed or reduced a dose (Lennes et al., 2016). Choi et al (2016) reported medication 
errors are primarily manifested in incorrect medication, dosage, and administration time. An 
observational study conducted by Delpeuch, Leveque, Gourieux, and Herbrecht (2015) found 
522 drug-specific questions or problems in 4,393 oncology-related prescriptions. Of the 
identified issues, 11.7% were due to underdosing and 8.9% to overdosing. Specifically related to 
medication administration, drug omissions accounted for 3.5% and inappropriate administrations 
for 14.1% of the errors noted in the study. 
Factors influencing errors.  A chemotherapy error is recognized as a multilayered 
variance, and the evidence for error recognition and prevention can clearly be delineated to 
include unit-based processes, system-based structures, and critical individual nursing behaviors. 
While evidence suggests that staff responsible for treatment preparation and administration are 
prone to mistakes, their errors seem to be greatly influenced by environmental conditions during 
critical safety-related tasks (Keers et al., 2016; Lennes et al., 2016; Kullberg et al., 2013; 
Schulmeister, 1999; Surbone & Rowe, 2015). Fyhr et al (2015) identify common problems 
include lack of training and competency assessment, inadequate guidance and feedback related 
to procedural tasks, failure to prioritize error prevention, ineffective communication, insufficient 
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safety barriers, and absence of event reporting mechanisms and risk analyses. Figure B3 depicts 
a root cause analysis of factors influencing chemotherapy errors in an Ishikawa (fishbone) 
diagram at the individual, unit, and systems level (ASCO, 2016; ASHP, 2015; CCO, 2012; CCO, 
2014; IHI, 2012; IOM, 1999a; IOM, 2013; Keers et al., 2013; Kloth, 2010; Lennes et al., 2016; 
Nelson et al., 2014; Neuss et al., 2013; Polovich, 2015; Polovich, et al., 2014; Schulmeister, 
2006; Schulmeister, 2008; Schwappach & Wernli, 2011; Walsh et al., 2009; Warren, 2014).  
System factors. Underlying ineffective system-based structures may be crucial 
contributors to the occurrence of medication errors, failing to support error prevention. These 
include lack of ineffective components or issues related to technology infrastructure, compliance 
with known best practices and recommended error prevention strategies, limited clinical tools 
and resources, lack of leadership support for error prevention, and not prioritizing the adoption of 
a safe culture (Farag et al., 2017; Fyhr et al., 2015; Hung et al., 2016; ISMP, 2016b; Richardson 
& Storr, 2010; Shulman, 2015). For example, a recent review of more than 2,500 medication 
errors revealed safety issues that include computerized ordering and documentation systems 
actively contributing to or failing to prevent errors, indicating a change at the systems level is 
needed to include standardized safety reporting (Amato et al., 2016). 
Unit-based factors. The context of each chemotherapy care unit must also be considered. 
Errors may result due to ineffective detail of error prevention tasks in written processes, 
inadequate policies and procedures, lack of safety prioritization by managers, insufficient nurse 
training and assessment for competency in critical behaviors, lack of communication in 
recognizing and reporting errors, and environmental concerns such as distractions, noise, and 
interruptions (Farag et al., 2017; Fyhr et al., 2015; Hung et al., 2016; ISMP, 2016b; Polovich et 
al., 2014; Richardson & Storr, 2010; Shulman, 2015).  
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Individual factors. Personal behaviors or characteristics of nurses and patients may 
contribute to errors. For nurses, deficient best practice knowledge, insufficient critical skills, 
failure to follow or unawareness of safety procedures, time and workload constraints with missed 
steps, and fear of retribution may be factors (Farag et al., 2017; Fyhr et al., 2015; Hung et al., 
2016; ISMP, 2016b; Richardson & Storr, 2010). Overdependence on computerized ordering and 
documentation systems is another issue, as these require human input and may fail to account for 
human error (Amato et al., 2016; Shulman, 2015). Patient factors may include lack of 
engagement, education or comprehension, and the presence of disparities or comorbidities (IOM, 
2013; Keers et al., 2013; Kloth, 2010; Lennes et al., 2016; Nelson et al., 2014). 
Accountability for Chemotherapy Error Prevention 
 Accountability for safe and ethical care, including adequate performance of critical skills 
and behaviors and the responsibility to disclose and investigate errors, are both individual and 
organizational expectations. Overall organizational culture is key to error reduction, and a shared 
goal between all levels of staff within an organization should state that errors are reduced as 
much as possible with the understanding that errors likely will never be eliminated (Benzer, 
Charns, Hamdan, & Afable, 2017; Schein, 2010; Shulman, 2015). Leaders must demonstrate 
knowledge and understanding about patient safety practices (IOM, 2013; Porter-O’Grady & 
Malloch, 2015; Schein, 2010; Shulman, 2015; Weir, 2014). Likewise, leadership and culture may 
impact the staff’s readiness or perception of the need for change based on the type and level of 
communication, motivation, and resources provided (Benzer et al., 2017). Transdisciplinary and 
multilevel awareness, attention, and vigilance surrounding error prevention must exist, along 
with assuring staff are willing and able to report safety issues without fear of punitive action 
(Fyhr et al., 2015; Porter-O’Grady & Malloch, 2015; Richardson & Storr, 2010; Shulman, 2015; 
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Surbone & Rowe, 2015). Specific to chemotherapy, pharmacovigilance across levels is important 
due to the use of high-risk agents with inherent toxicities, and the complex management of 
patients between care settings (ASCO, 2016; Edwards & Bencheikh, 2016; IOM, 2013).   
Systems level accountability. Without prioritizing a culture of safety, a system is highly 
vulnerable to errors (Shulman, 2015). At the systems level, the integral components needed to 
transform practice and facilitate chemotherapy error prevention are grounded in an environment 
and culture that cultivate excellence, support staff needs, and prioritize safety to minimize risk 
and harm (ASCO, 2016; IOM, 2013; Porter-O’Grady & Malloch, 2015; Schein, 2010; Weir, 
2014). The literature urges organizations to strengthen the underlying processes that are 
considered the required drivers of safe chemotherapy administration by developing preventive 
chemotherapy error management strategies that comply with clinical, regulatory, and 
reimbursement guidelines and standards to avoid penalties and decrease the risk for catastrophic 
outcomes (ASCO, 2016; Fyhr et al., 2015; IOM, 1999b; IOM, 2013; Weber & Sidorov, 2014).  
 Unit level accountability. Literature reveals work cultures are often prohibitive to error 
reporting, evoking fear of retribution and punitive action (Brady et al., 2009; Fyhr et al., 2015; 
Harris & Northfelt, 2005; Hung et al., 2016; IOM, 2006; IOM, 2013; Schulmeister, 2006; 
Sheridan-Leos, 2007; Trbovich et al., 2010). The context of each nursing unit along with staff 
and patient characteristics must be considered. Delivering educational content is likely to be 
easier in a non-punitive, non-blaming culture where training and experience in error prevention 
strategies is prioritized (McNab, Bowie, Ross, & Morrison, 2016). Without a true culture of 
safety at the unit level, factors contributing to errors may be the result of lack of awareness that 
guidelines exist, attitudes and perceptions of individuals within the healthcare team, lack of 
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incentives to comply, and level of difficulty to integrate into current practice, policies, and 
procedures (Hung et al., 2016; Richardson & Storr, 2010; Weber & Sidorov, 2014).  
 Individual level accountability: Nursing. Because error prevention is inherent in 
professional nursing practice, licensure regulations, codes of ethics, and practice scope and 
standards cannot be overlooked. Oncology nursing standards (see Table A2) expect individual 
nurses to be accountable for developing and maintaining competence in the treatment consent 
process, and demonstrating that competency through pretreatment verification, safe treatment 
administration, and post-treatment toxicity management (Brant & Wickham, 2013; Neuss et al., 
2013; Neuss, et al., 2016; Polovich et al., 2014). With the development of critical behaviors 
related to error recognition and reporting, nurses demonstrate accountability, fidelity, and 
veracity while upholding the ethical principles of beneficence and nonmaleficence (ANA, 2015; 
Brant & Wickham, 2013; Fry, Veatch, & Taylor, 2011; Surbone & Rowe, 2015).  
Individual level accountability: Patient. The role of the patient in error prevention is 
gaining attention. Some drug safety and quality improvement experts advocate for innovative 
assessment and integration of pharmacovigilance that includes assessing for and integrating 
patient and family engagement in risk communication (Smith & Benattia, 2016). This patient-
centric approach is rooted in the incentivization of quality and safety reporting outcomes 
(AHRQ, 2016; ASCO, 2016; Etchegaray et al., 2016). Patients and family able to identify factors 
contributing to errors can assist in recommending changes to organizational processes. A study 
by Etchegaray et al. (2016) revealed patients questioned staff qualifications, safety procedures, 
and communication issues as factors likely contributing to errors.  
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Chemotherapy Error Prevention Strategies 
 Errors continue to be a quality improvement priority due to their high risk for patient 
harm. Holding assumptions that systems are safe leads to the likelihood for increased errors. 
Therefore, strategies aimed at continual evaluation of the underlying safety processes and 
investigation of error events are essential. Ongoing vigilance at all levels within an organization 
will provide the highest assurance that that safety is prioritized (Shulman, 2015). Lennes et al. 
(2016) state improvement projects can result in an interprofessional approach to measuring and 
reporting chemotherapy errors, including policies and procedures to support the needed changes. 
Evidence-based practice recommendations for error prevention in the literature include the need 
for adoption of critical individual behaviors to prevent chemotherapy errors, and strong 
organizational processes to drive the development and utilization of those critical behaviors 
(ASHP, 2015; IHI, 2012; IOM, 2013; ISMP, 2007; ISMP, 2010; ISMP, 2016a; ISMP, 2016b; 
Kloth, 2010; Neuss et al., 2013; Polovich, 2015; Polovich et al., 2014).  
 Critical individual nursing behaviors. For the purpose of this project, critical 
individual nursing behaviors are essential tasks that promote the prevention of chemotherapy 
errors as noted in practice guidelines and standards. These tasks include verifying the patient’s 
identity, height and weight, understanding of the treatment, medication lists, and consent to treat. 
A detailed review of chemotherapy regimen orders is also an expectation just prior to 
administration, and should be performed both individually and simultaneously with another 
chemotherapy-competent individual. Treatment orders are verified for appropriateness of dose, 
dilution, sequence, route of administration, and duration of treatment based on standardized 
protocol and regimen information. Administration tasks involve assuring the appropriate route, 
sequence, and duration, and assessment of the site and patient for immediate complications. 
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Documentation standards include noting the verification tasks and assessment findings 
throughout the pretreatment, administration, and post-treatment phases (ASHP, 2015; IHI, 2012; 
IOM, 2013; ISMP, 2007; ISMP, 2010; ISMP, 2016a; ISMP, 2016b; Kloth, 2010; Neuss et al., 
2013; Polovich, 2015; Polovich et al., 2014). 
 Supporting organizational processes. For the purpose of this project, organizational 
processes include policies, procedures, documentation standards, and quality improvement 
monitoring that promote and support the prevention of chemotherapy errors. Underlying 
organizational processes, such as technology infrastructure, policies, and procedures must 
support error prevention and reduction strategies across the organization. The essential processes 
noted in practice guidelines and standards include institutional requirements for chemotherapy 
training with competency assessment. Policies and procedures also need to consider sufficient 
patient information access and order verification resources, medical record documentation 
stipulations, quality improvement monitoring, error reporting procedures, and performance 
appraisal processes (ASHP, 2015; IHI, 2012; IOM, 2013; ISMP, 2007; ISMP, 2010; ISMP, 
2016a; ISMP, 2016b; Kloth, 2010; Neuss et al., 2013; Polovich, 2015; Polovich et al., 2014). 
Chemotherapy Error Prevention Education for Nurses 
 A clear gap identified relates to how error prevention information shared through a 
chemotherapy course is translated into individual practice and organizational process change. 
Providing comprehensive education, regular competency evaluation, and simulation of error 
events are recommended tools for raising awareness of critical behaviors and processes that can 
enhance the safety of practice (Daupin, Atkinson, Bedard, Lebel, & Bussieres, 2016; McNab et 
al., 2016; Polovich et al., 2014; Neuss et al., 2013; Neuss et al., 2016). This project was an initial 
step in evaluating the need for, and appropriateness of, error prevention education for patient 
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safety enhancement. Additionally, the project sought to determine perception of barriers to 
changing practice at the individual and organizational levels.   
 The ONS/ONCC Chemotherapy and Biotherapy Certificate course addressed in this 
project is an established nursing education program. Components of the course address safe 
chemotherapy administration through evidence-based error prevention strategies compiled from 
practice guidelines and standards. Each participants’ initial reaction to learning and knowledge 
retention were evaluated after didactic presentation of the course content (ONS, 2016a). This 
project furthered the program evaluation to assess integration of knowledge into practice.  
Barriers to Practice Change 
While the need to identify the impact of education on error prevention strategies was the 
priority of this project, perceived barriers to practice change were also explored. A published 
literature review comprised of eleven articles reveals limited knowledge about how personal and 
professional aspects of nursing leadership, collaboration, and empowerment may impact patient 
safety (Richardson & Storr, 2010). The authors opine that nurses are the ideal drivers of quality 
and safety “because of their unique proximity to patients” (Richardson & Storr, 2010, p. 12).  
Safety culture. According to a survey from the Agency for Healthcare Research and 
Quality (AHRQ) (2016), about 45% of hospital employees perceive their organization reacts to 
errors in a nonpunitive manner. A recent survey of 246 registered nurses explored how the safety 
climate of a workplace may impact safe medication practices (Farag, Tullai-McGuinness, 
Anthony, & Burant, 2017). In addition to multiple personal factors, including self-confidence, 
the context of care was found to influence the safety of medication administration. Trust in the 
organization and perceived leadership passivity were reported as possible hindrances to safe 
practice development and error reporting (Farag et al., 2017).  
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Approach to errors. Supporting infrastructure must include technology, training, 
policies, and procedures that prioritize safety. Emphasis should be placed on reliable electronic 
resources and error-reducing systems, and error reporting that is elevated appropriately (AHRQ, 
2016). A survey conducted by Hung, Chu, Lee, and Hsaio (2016) suggests safety may be 
threatened when managers and peers perceive a nurse who reports an error to be incompetent or 
causing trouble, possibly resulting in the under-reporting of medication errors or limited 
willingness to report them (Hung et al., 2016).   
Fyhr et al. (2017) iterate that both a reactive and proactive safety approach are important 
organizational components that affect safe practice. However, a proactive approach 
communicates that leaders have prioritized safety, through training, guidance, communication, 
and error reporting. With a proactive approach, nurses may have an enhanced sense of resilience, 
which is especially important with increasingly complex scenarios, such as chemotherapy care, 
in which safety risks are elevated and error prevention is vital (Fyhr et al., 2017). 
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Section Two 
Theoretical Basis 
Theoretical Frameworks 
 For the purpose of this project, the New World Kirkpatrick Model of Evaluation 
(NWKM) (Kirkpatrick Partners, 2015) provided an opportunity to address the impact of 
knowledge by assessing whether individual practice behavior and supporting process changes 
were perceived as needed or were initiated following chemotherapy education. Since the NWKM 
does not assess challenges to changing practice, the Knowledge-to-Action framework (KTA) 
(Graham et al., 2006) was used to address barriers and facilitators to knowledge integration 
based on the context of the practice environment and specific stakeholder considerations.  
Following the concepts in the NWKM and KTA frameworks, the project survey themes (See 
Table A5) assisted in describing how knowledge, critical individual nursing behaviors, and 
supporting organizational processes may be applied to chemotherapy error prevention. 
New World Kirkpatrick Model of Evaluation  
 The NWKM development is based on an organization’s desire to evaluate how training 
impacts job performance and outcomes. Assessing the impact of critical behavior change and 
application of knowledge that demonstrates desired compliance with practice guidelines and 
standards following a training intervention is recognized as a high level educational outcome 
based on the four levels of evaluation within the NWKM (Kirkpatrick Partners, 2009).  
NWKM evaluation levels. Within this model, Level One evaluation assesses the 
participant’s reaction to the learning process and information presented. Level Two evaluation 
assesses learning based on retention of knowledge presented. The NWKM Level Three assesses 
if behavior change occurs as a result of applying the knowledge gained to improve work-
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related outcomes. Level Four assesses actual work-related outcomes resulting from the applied 
behavior changes (Kirkpatrick & Kirkpatrick, 2006; Kirkpatrick Partners, 2009).  
 NWKM Level Three. For the purpose of this project, the NWKM evaluation level of 
focus is Level Three. Level Three determines “how much transfer of knowledge” and “what 
change in behavior” occurs after training when the participants return to work (Kirkpatrick & 
Kirkpatrick, 2006, p. 52). Level Three also evaluates facilitators and barriers to behavior change 
that drive knowledge integration, including “processes and systems that reinforce, encourage and 
reward performance of critical behaviors on the job” (Kirkpatrick & Kirkpatrick, 2006, p. 52). 
The NWKM rationale for evaluating at Level Three is that optimal outcomes cannot be achieved 
“unless a positive change in behavior occurs” (Kirkpatrick & Kirkpatrick, 2006, p. 61).  
 In chemotherapy error prevention education, Levels One and Two verify knowledge of 
guidelines and standards has been retained through full attendance at a comprehensive program 
that includes learner assessment through completion of discussion postings and a post-test. 
However, organizational goals and objectives to improve safe practice behaviors leading to 
prevention of chemotherapy errors and the resulting patient outcomes cannot truly be attained 
unless learning is applied to practice. Additionally, individual behaviors need organizational 
processes that support training and its application to practice, both of which comply with 
guidelines and standards. Moreover, participants are positioned to influence change, yet barriers 
may exist that should be identified to promote the next step of developing tools to overcome 
barriers and facilitate change (Kirkpatrick & Kirkpatrick, 2006).  
 A detailed look at Level Three of the NWKM as it applies to this project assesses the 
effect of learning on critical behaviors, required drivers, and on-the-job learning. Essentially, the 
components of Level Three describe accountability for learning, and how knowledge is applied 
ASSESSING THE IMPACT OF CHEMOTHERAPY EDUCATION 26 
to practice through critical behaviors once the learner returns to the workplace, and how the 
organization is supportive with required processes to drive the needed change.  
 Critical behaviors. Critical behaviors are defined in the NWKM as, “specific actions, 
which, if performed consistently on the job, will have the biggest impact on the desired results” 
(Kirkpatrick Partners, 2015, p. 7). For this project, the critical individual nursing behaviors are 
strategies previously identified in evidence-based clinical guidelines, practice standards, and 
best practice recommendations that assist the nurse in achieving optimal chemotherapy error 
prevention.  
 Required drivers. The NWKM also recognizes the need for required drivers or processes 
that the organization implements to assist in applying the critical behaviors to practice. Required 
drivers are defined in the model as, “processes and systems that reinforce, monitor, encourage 
and reward performance of critical behaviors” (Kirkpatrick Partners, 2015, p. 7). For this 
project, the required drivers are considered organizational processes and include the 
foundational policies and procedures that support the prevention of chemotherapy errors.  
 On-the-job learning. The NWKM purports that on-the-job learning includes the 
expectations that individuals are responsible for maintaining the learned knowledge and skills, 
and employers support and share in the responsibility for optimal performance (Kirkpatrick 
Partners, 2015). The NWKM includes steps to successfully determine whether knowledge is 
applied to practice. For this project, individual accountability is demonstrated through 
application of practice-based critical nursing behaviors which are supported by the 
organizational processes to prevent chemotherapy errors. Additionally, the Knowledge-to-
Action framework, discussed later, describes the phases of knowledge translation to practice.  
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NWKM evaluation steps. The steps involved in a NWKM Level Three evaluation are to 
define expectations of job performance, link learning to work-related tasks, and assess 
integration of knowledge into work-related behaviors. The model recommends allowing time for 
behavior change to take place, with three to six months being most realistic. Lastly, the NWKM 
suggests using well-designed interviews or surveys should provide data to determine if behavior 
and process change occurred following training. Furthermore, the NWKM description of options 
for Level Three evaluation include the use of online forms to measure whether distant learners 
have been involved in change processes (Kirkpatrick & Kirkpatrick, 2006). For this project, the 
NWKM Level Three evaluation is demonstrated by defining expectations related to error 
prevention tasks, and assessing the integration of knowledge into practice through the use of a 
web-based survey that describes behavior and process change following training. 
Model application to knowledge in health care. The NWKM is an outcome-oriented 
evaluation model that emphasizes learning outcomes directly related to a training program. It 
focuses on how the knowledge is used by the learner (Dubrowski & Morin, 2011).  The NWKM 
has been adapted to address practice outcomes following education of healthcare professionals 
(Cox, Seymour, & Stefanidis, 2015). All four evaluation levels have been utilized to measure the 
effectiveness of various types of healthcare training, assessing training on multiple levels that 
include learner reaction, knowledge retention, behavioral change, organizational impact, and 
return-on-investment (Salas et al., 2009). However, fewer than 40 percent of the literature that 
describe the model applied to practice address behavioral changes or Level Three (Cox, 
Seymour, & Stefanidis, 2015; Onyura et al., 2016). Literature describing healthcare quality 
improvement initiatives and program evaluations that utilize Level Three of the NWKM 
emphasize the need for progression from learning and retention of knowledge to changed 
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behavior within the clinical setting. At Level Three, the primary stakeholders are the learners and 
healthcare organizations (Dubrowski & Morin, 2011).  
 Practice-based competency assessment within the literature include examples of how the 
NWKM Level Three evaluation has been applied to evaluate knowledge translation to practice in 
healthcare. The NWKM has been utilized to evaluate pain management curricula and clinical 
competence related to procedural knowledge of healthcare professionals (Dubrowski & Morin, 
2011). Dewey, Ghulyan, and Swiggart describe using the NWKM to effectively evaluate 
translation of knowledge to practice for providers who completed an educational program and 
were able to align prescribing processes of controlled substances with clinical practice guidelines 
and standards (2015). A study demonstrating improvement in knowledge, attitude, and behaviors 
with intent to improve practice is documented by Goucke, Jackson, Morriss, and Royle (2015). 
Roos et al. (2014) suggest that peer-, self-, and expert-assessment indicated a transfer of learning 
into professional practice performance and helped to identify incentives and barriers as well as 
motivation for change. A systematic review of the use of the Kirkpatrick Model evaluation levels 
in medical education by Leslie et al. (2013) found 21 healthcare program evaluation studies in 
which the most commonly reported outcome was participants’ behavior change, or Level Three 
evaluation with outcome indicators including work delivery, skills, and productivity. The same 
review article identified the majority of program evaluations included self-reported behavior 
outcomes through interview or survey designs (Leslie et al., 2013).  
Knowledge-to-Action Framework  
 The Knowledge-to-Action (KTA) framework includes two components: 1)  Knowledge 
Creation, in which content of the desired knowledge is generated, provided, and synthesized; and 
2) the Action Cycle in which problem-specific processes are followed leading to the translation 
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and application of knowledge (Graham et al., 2006). Knowledge Creation and the Action Cycle 
impact each other and may be completed sequentially or simultaneously. Because the knowledge 
has already been generated, provided, and synthesized through participant involvement and 
successful completion of the chemotherapy educational program, the KTA Action Cycle was 
utilized for this project. The Action Cycle appropriately includes specific needs of the involved 
stakeholders (learners and organizations) and recognition of barriers and facilitators with 
knowledge integration; this may also help identify potential tools that assist with error 
prevention guideline and standard implementation within the practice environment.  
 KTA Action Cycle phases. The Action Cycle encompasses seven phases that lead to the 
actual implementation of knowledge, with the first five phases being appropriate for this project, 
as described below (CIHR, 2014; Field, Booth, Ilott, & Gerrish, 2014).  
 Phase One: Identify the Knowledge-To-Action gaps. Identifying the gaps in applying 
knowledge to practice is the basis of knowledge implementation. Learning needs assessments 
and questionnaires help to identify these gaps (CIHR, 2014).  
 Phase Two: Adapt knowledge to local context. Although guidelines and standards 
provide evidence-based practice recommendations, the adaptation of guidelines is a necessity 
based on the context of each practice environment. Individualizing guidelines to align with 
organizational goals may help improve acceptance, adherence, and performance (CIHR, 2014).  
 Phase Three: Assess barriers to knowledge use. During the individualization process in 
Phase Two, barriers to knowledge use are likely to be identified. The KTA Action Cycle 
suggests using expert consensus to determine appropriate guidelines and standards for a care 
setting, and a questionnaire or interview process to gather data regarding factors affecting 
guideline implementation (CIHR, 2014).  
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 Phase Four: Select, tailor, and implement interventions. Interventions addressing the 
facilitation of knowledge into practice may include educational programming, quality initiatives, 
and clinical support tools. Assessing for the presence and need for these options may be helpful 
in improving compliance with practice guidelines and standards (CIHR, 2014).  
 Phase Five: Monitor knowledge use. Initial use of knowledge may be attitudinal or 
conceptual, eventually resulting in demonstration of knowledge use through behavior change. 
Strategic use of knowledge through quality improvement can then be demonstrated to enhance 
supporting organizational processes (CIHR, 2014).  
 Model application to knowledge in health care. The KTA framework has been used in 
in various healthcare disciplines to evaluate practice change as a result of research or education 
integration (CIHR, 2014). A systemic review notes KTA as one of the most frequently cited 
conceptual frameworks for knowledge translation, and the Action Cycle is primarily used in 
studies evaluating barriers and facilitators within work environments and stakeholder groups 
(Field, Booth, Ilott, & Gerrish, 2014). Specific to nursing, the Action Cycle of the KTA 
framework has been utilized to propose the integration of patient decision support into nursing 
education (Stacey, Higuchi, & Menard, 2009). Bjork et al. (2013) used the KTA framework to 
assess how nursing skill performance is measured, and barriers to correct skill utilization. 
Additionally, Petzold, Korner-Bitensky, & Menon (2010) assessed the use of educational focus 
groups and interviews to address barriers and facilitators to interprofessional practice change.  
Recommendations Summary for Program Evaluations 
Current Program Evaluation Process 
At the time of this project implementation, the post-program evaluation process for the 
ONS/ONCC Chemotherapy and Biotherapy Certificate course measured the learner’s initial 
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reaction. Evaluation questions asked participants to rank the extent to which the course met 
stated goals and objectives. The evaluation also asked participants to rate the effectiveness of the 
online platform and teaching-learning strategies. The data gathered from the post-program 
evaluation correlates with Level One of the NWKM and Phases One and Two of the KTA 
framework, evaluating learner reaction to educational content (CIHR, 2014; Field et al., 2014; 
Kirkpatrick Partners, 2009). Additionally, the course required completion of a post-test to 
evaluate retention of the knowledge. Successful completion of the post-test (a score of at least 
80%) is associated with Level Two evaluation of the NWKM (Kirkpatrick Partners, 2009).  
Program Evaluation Needs 
At the time of this DNP project implementation, the ONS/ONCC program evaluation 
process did not assess for perceived or actual initiation of change based on knowledge gained, or 
the course participants’ perception of barriers to change. This project involved evaluating higher 
level educational outcomes based on the NWKM and KTA frameworks, addressed gaps related 
to applying knowledge to practice, and considered the context of the chemotherapy care setting. 
This project also identified needs related to the development of critical nursing behaviors and 
supporting organizational processes by assessing barriers to change. This evaluation correlates 
with Level Three of the NWKM, and Phases Two, Three, Four, and Five of the KTA framework 
(CIHR, 2014; Kirkpatrick & Kirkpatrick, 2006). Primary stakeholders in this higher level 
evaluation process included the nurse learners and organizational decision-makers, both charged 
with adopting behaviors and processes to promote optimal patient safety. 
Overall Program Evaluation and Project Survey Themes  
The identified clinical problem for this project was to determine if nurse participants 
perceived the need to change or if they actually initiated practice change following education to 
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more effectively comply with specific evidence-based chemotherapy prevention strategies 
presented in the ONS/ONCC course. The clinical question, In nurses who have completed a 
comprehensive chemotherapy education program, was practice change to improve error 
prevention initiated within six months? guided the development of the survey components within 
this project. The answer to the question sought to determine nurses’ perception specifically 
related to the implementation of evidence-based critical behaviors and organizational processes 
that reduce the potential for chemotherapy errors. Table A5 delineates the appropriate 
components of the NWKM and phases of the KTA framework that assess change in critical 
nursing practice behaviors and supporting organizational processes to comply with error 
prevention strategies presented in the ONS/ONCC chemotherapy course. Specific survey 
components align with the clinical questions, addressing the following overall three themes.  
 Nurse participants’ perception of need for individual and organizational change.  
 Nurse participants’ initiation of individual and organizational change.  
 Nurse participants’ perception of barriers to individual and organizational change.  
Utility and Feasibility of Program Evaluation for Practice Change 
 Identifying the gaps in applying knowledge to practice is the basis of knowledge 
implementation. Learning needs assessments help to identify these gaps. ONS evaluates learning 
needs through questions about desired topics of interest in post-program evaluations and 
anecdotal conversations with new chemotherapy nurses and chemotherapy-competent nurses. 
Email submissions to ONS staff also demonstrate a need for guidance when integrating 
knowledge gained into policies, procedures, and practice.  
 One of the identified learning needs involves providing education specifically addressing 
error prevention behaviors for point-of-care staff, and guiding the development of organizational 
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structures and processes that support those behaviors. The importance of this need is emphasized 
through the expectation of compliance with guidelines and standards that reduce the risk for 
medication errors. Furthermore, demonstration of alignment with guidelines and standards is an 
expectation of some accreditation, reimbursement, and regulatory agencies such as the ONS, 
American Society for Clinical Oncology (ASCO), Joint Commission (JC), U.S. Department of 
Health and Human Services (USDHHS) through provisions set forth in the Affordable Care Act 
(ACA), and reports from the National Academies (formerly the Institutes of Medicine or IOM),  
(IOM, 2013; JC, 2016; Neuss et al., 2013; Polovich, Olsen, & LeFebvre, 2014; USDHHS, 2014).   
 At the time of this project implementation, the identified learning need for chemotherapy 
error prevention strategies was being addressed through content interspersed in various areas and 
activities within the ONS/ONCC course. However, the effective use of knowledge attained from 
the course to inform the need for change at the individual and organizational levels was not 
known. Used of the NWKM and KTA frameworks in this project helped to identify the 
effectiveness of the course and further educational needs that may assist nurses and organizations 
in complying with guidelines and standards for safe chemotherapy administration.  
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Section Three 
Recommendations for Practice Change to Prevent Chemotherapy Errors 
 This clinical inquiry assessed the impact of chemotherapy education for nurses on 
practice behaviors that minimize the risk for errors, thereby improving patient safety. Of high 
importance to this project was the appraisal of the evidence suggesting that, 1) most 
chemotherapy errors occur during prescriptive or order documentation, 2) most errors are 
recognized before reaching the patient, 3) most are typically the result of underlying system 
factors, and 4) many are discovered during critical nursing tasks in the pretreatment phase. These 
four findings in the literature pinpoint nurses as vitally important in error prevention (Keers et 
al., 2013; Polovich, 2015; Polovich et al., 2014; Shulman, 2015; Walsh et al., 2009; White et al., 
2010). Based on the critical appraisal of evidence and analysis of gaps, five practice 
recommendations are proposed to enhance and support the nursing role in chemotherapy 
error prevention as encompassed within the survey themes and components.  
Recommendation One: Provide Comprehensive Chemotherapy Education for Nurses  
 The most apparent notation gained from the literature leading to recommendations for 
change through implementation of this project is that educational and supportive needs of nurses 
to provide vigilant and safe chemotherapy care cannot be understated (Neuss et al., 2013; 
Polovich, 2015; Polovich et al., 2014). The outcomes of this project describe the importance and 
impact of a comprehensive chemotherapy education program on nursing practice. Any perceived 
need for change in error prevention behaviors and organizational processes that are essential to 
support those behaviors, demonstrate the need for initial and ongoing chemotherapy education.  
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Recommendation Two: Integrate Practice Guidelines and Standards  
 Methods for integrating strategies that promote chemotherapy error prevention in nursing 
practice are unclear in the literature. Some studies report improved compliance to guidelines and 
standards in addition to decreased medication error rates following electronic order and 
documentation implementation that include components of guidelines and standards (ASCO, 
2016; ASHP, 2015; CCO, 2012; CCO, 2014; Keers et al., 2013; Kloth, 2010; Lennes et al., 2016; 
Nelson et al., 2014; Walsh et al., 2009; Warren, 2014; Weber & Sidorov, 2014). In anecdotal 
reports through inquiries to ONS, nurses frequently seek guidance when faced with unclear order 
verification processes in the workplace and when attempting to make recommendations for 
policy and procedure revision to practice leaders. Practice guidelines and standards stipulate the 
various components of chemotherapy orders, yet chemotherapy nurses continue to identify and 
verbalize gaps between the error prevention evidence presented in the ONS/ONCC 
chemotherapy course and what actually is supported and recognized as essential in practice. 
These gaps suggest the need for evaluating whether standardized policies, procedures, and 
processes specific to chemotherapy settings comply with practice guidelines and standards, and 
if educational opportunities regarding the guidelines and standards may assist with their 
integration. This project describes whether nurses who have participated in a comprehensive 
chemotherapy education program perceived essential chemotherapy error prevention strategies 
as already in place, if integration is needed, if change is initiated to allow the integration to 
proceed, and potential barriers to the integration.  
Recommendation Three: Assess Need for Practice Change Related to Critical Behaviors  
  The oncology environment changes rapidly, and treatment for cancer entails multiple 
patient safety issues due to complex chemotherapy regimens. Nurses are the last checkpoint prior 
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to the administration of high-alert antineoplastic agents that require special handling and have 
narrow therapeutic indices with an increased risk for a life-threatening event should an error 
occur. Individual nurses hold responsibility to accept, adopt, advocate for, and embrace change 
that promotes evidence-based practice and optimization of safe care (Brant & Wickham, 2013; 
Polovich, 2015; Polovich et al., 2015). They must practice and model critical safety behaviors, 
and request revision of essential organizational processes that do not comply with safe practice 
recommendations (AACN, 2006; Brant & Wickham, 2013; IOM, 2013; Polovich, 2015; Porter-
O’Grady & Malloch, 2015; Schein, 2010). A noticeable gap exists between attaining and 
applying knowledge to prevent chemotherapy errors suggests the need for a more standardized 
approach to educating nurses with enhanced support through organizational error prevention 
processes. Therefore, this project was beneficial in determining how education affects the 
application of error prevention knowledge.  
Recommendation Four: Implement Organizational Processes to Support Practice Change  
 A chemotherapy error is an undesirable outcome that requires investigation at all 
organizational levels. At the systems level, change may be needed for quality improvement, risk 
reduction, and standards compliance. A significant error may diminish patient outcomes, cause 
undesirable public attention and financial effects, increase insurance costs, and impact the 
psychosocial status of staff and patients. The integral components needed to transform practice 
and facilitate error prevention are grounded in a culture that prioritizes safety to minimize harm 
(ASCO, 2016; IOM, 2013; Porter-O’Grady & Malloch, 2015; Schein, 2010; Weir, 2014). 
 A root cause analysis (See Figure B1) identifies potential factors contributing to 
chemotherapy errors within various organizational levels. Structures and processes should 
integrate evidence-based recommendations for error prevention, recognition, and reporting. An 
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innovative system approach is the desired result, complying with clinical, regulatory, and 
reimbursement standards to avoid penalties and decrease the risk for catastrophic outcomes 
(ASCO, 2016; IOM, 2013).  
Recommendation Five: Prioritize a Culture of Safety 
The safety climate within a healthcare organization may impact safe medication 
practices. Remembering to learn from past mistakes is a barrier to improvement because “when 
harmful events are forgotten, they are likely to be repeated” (Macrae, 2016, p. 1). A prioritization 
on patient safety should be adopted, including leadership support and integration of strategies to 
increase empowerment, awareness, and proactive recognition of errors (Fyhr et al., 2015; Hung 
et al., 2016). Assessing and assuring nurses’ competence and confidence related to error 
identification, and having trust in the reporting procedure are crucial. These are achieved through 
education, technology and equipment training, with solid design of policies and procedures that 
clearly demonstrate patient safety is a priority (Faraq et al., 2017; Hung et al., 2016). 
Project Implementation Based on Recommendations 
Organizational Mission and Strategic Plan 
 By assessing practice change following an ONS educational intervention, this project 
aligns with the ONS mission, vision, and values that guide organizational activities (ONS, 
2017a). The ONS mission to advance excellence in oncology nursing and quality cancer care and 
its vision to lead the transformation of cancer care are encompassed in the provision of 
comprehensive chemotherapy education. The ONS core values of providing an innovative 
learning opportunity, promoting excellence in oncology nursing and quality patient care, and 
advocating for people with cancer are relevant to this project (ONS, 2017a). Furthermore, the 
theoretical models that guided this project promote high level educational outcomes, outlining 
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steps for evaluating the effect of training on practice behaviors and delineating the phases of, and 
potential barriers to, knowledge integration to effect practice change. The recommended practice 
changes may improve patient safety outcomes through better chemotherapy error prevention. 
Evidence-Based Practice Model to Implement Change 
  Within the series of IOM reports that revealed major variances in care leading to 
significant preventable harm, recommendations were included. A key recommendation was to 
enhance evidence-based practice, or EBP (IOM, 1999a; IOM, 1999b; IOM, 2001; IOM, 2003; 
IOM, 2010). Specific to nursing, an improvement recommendation focuses on the application of 
knowledge and research to practice, demonstrating EBP (Stevens, 2013). The EBP process 
involves appraising the current state of knowledge regarding a specific clinical issue to develop 
interventions that support and improve care processes and patient outcomes. Identifying and 
implementing best practices to inform safe, quality care is inherent in EBP.  
The Evidence-based Advancing Research and Clinical Practice through Close 
Collaboration (ARCC©) Model (see Figure B4) provides a framework for system-wide use when 
implementing and sustaining a culture that supports EBP and achievement of quality outcomes.  
The ARCC© Model is intended to enhance the organizational culture and individual clinicians’ 
beliefs, knowledge, skills, and resources related to EBP, leading to improved and sustainable 
patient outcomes (Melnyk, 2012; Melnyk & Fineout-Overholt, 2015; Melnyk, Fineout-Overholt, 
Gallagher-Ford, & Stillwell, 2011; Melnyk et al., 2017). When evidence-based care is “delivered 
in a context of caring and in a supportive organizational culture, the highest quality of care and 
best patient outcomes can be achieved” (Melnyk et al., 2011, p. 57).  
Central to the integration of the ARCC© Model is cultivation of a culture that promotes 
evidence-based decisions through the effective use of resources, education, and skill attainment, 
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and identifies EBP champions and mentors (Dang et al., 2015; Melnyk, 2012; Melnyk, Fineout-
Overholt, Giggleman, & Choy, 2017; Melnyk, Fineout-Overholt, Giggleman, & Cruz, 2010). 
Both individual and organizational EBP implementation are addressed within the ARCC© 
Model, including barriers and facilitators to change within the context of the care environment, 
aligning it well with this project. The ARCC© Model cites cognitive behavioral theory (CBT) as 
a foundation for EBP implementation, specifically focusing on individual nurse perceptions 
about the importance and value of practice change to improve outcomes and how organizational 
leadership provides support for the change process (Dang et al., 2015; Melnyk, 2012).  
The ARCC© Model is an appropriate pathway to EBP when approaching chemotherapy 
error prevention. It is widely used by interprofessional teams with EBP champions to implement 
safety-related protocols in acute care and community organizations. It has also been identified as 
a key point-of-care improvement model for addressing patient safety in high-reliability 
organizations (Melnyk, 2012; Melnyk, Fineout-Overholt, Giggleman, & Choy, 2017;  Melnyk, 
Fineout-Overholt, Giggleman, & Cruz, 2010). The model depicts a decision tree based on 
problem exploration and prioritization based on strengths and weaknesses, and progresses toward 
translating evidence to inform a practice change and improve outcomes (Dang et al., 2015).  
The steps of the EBP process are embedded in the ARCC© Model: 1) cultivate a spirit of 
inquiry, 2) ask PICOT-formatted clinical questions, 3) search for the best evidence, 4) integrate 
the evidence into practice change decisions while considering clinical expertise and patient 
preference, (5) evaluate the outcome of the practice change; and (6) disseminate the outcomes 
(Dang et al., 2015). This project addresses the first four steps of the EBP process, along with 
dissemination of findings. For the purpose of this project, initial ARCC© Model steps of 
assessing organizational culture and readiness for EBP, identifying major barriers to EBP, 
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and exploring clinicians’ perceptions about a specific safety-related practice change are being 
addressed.  This initial data can be helpful in determining subsequent steps specific to 
organizational implementation of EBP. The project may lead to the development of education 
and tools to assist with full integration of the practice change recommendations and further 
studies to describe the impact of changes on safety and quality outcomes (Dang et al., 2015; 
HRSA, 2011; Melnyk, 2012; Warren, 2014). 
Project Design and Methods 
Sample 
Data was collected from a subset of registered nurses who completed the ONS/ONCC 
Chemotherapy Biotherapy Certificate Course between October 1, 2015, and March 31, 2016. 
The survey was conducted between October 31, 2016, and December 16, 2016. This time period 
was selected since evidence suggests practice change following the accumulation of knowledge 
from educational interaction generally takes at least six months and up to two years to achieve 
depending on the work environment and change intended to be made (Weber & Sidorov, 2014).  
Sampling design. A convenience sample was used consisting of registered nurse 
participants who reside in the U.S. and have successfully completed the ONS/ONCC course 
within the stated six month time frame. Through the use of questions specific to personal and 
professional practice characteristics, this convenience sample allows for identification of trends 
and relationships in applying knowledge to practice among different groups of nurses who are 
administering chemotherapy in a variety of care settings.  
 Sample size. More than 50,000 registered nurses completed the ONS/ONCC 
Chemotherapy Biotherapy Certificate Course between January 1, 2014, and June 30, 2016. Not 
all of these nurses are ONS members. Historical data from this course indicates between 82-97% 
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of participants successfully complete the program based on course requirements (ONS, 2017b). 
The number of international nurses taking and completing the course is not yet known but is 
expected to be < .05% of the total number of course participants (ONS, 2017b). Therefore, the 
total number of course participants within the ONS database is approximately 39,000-45,500. 
Since the invited project participants completed the course over a specific six months, the 
number of eligible participants was 5,471. 
Sampling procedure and inclusion. The secure program evaluation system currently in 
use by the ONS was utilized to identify registered nurses who have successfully completed the 
course during the specified six month time period from October 1, 2015, through March 31, 
2016. Course requirements that determined successful completion of the ONS/ONCC course 
during that time frame were, 1) submission of four discussion postings, and 2) obtaining a score 
of 80% or higher on the course post-test. The usual successful pass rate for this course is 83-89% 
of participants (L. Richardson, personal communication, October 17, 2016). Those not achieving 
successful completion requirements were not eligible to participate in this project, and were not 
identifiable in the program evaluation database. While the course is available globally, only 
nurses practicing in the U.S. were included since the practice guidelines and standards addressed 
in the survey are those established and recognized in U.S. oncology settings.  
The secure, integrated customer database currently in use by the ONS provided participant 
email addresses what were de-identified for other components of identification prior to being 
available to this DNP student. One initial invitation to participate in a web-based survey 
questionnaire was sent by email to all eligible nurse at the same time, with three reminders sent 
to non-participants two, four, and five weeks after the initial invitation. The survey was available 
for six weeks then closed to further responses. The survey was administered by ONS staff.  
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Practice Setting and Context 
The setting for this project was the Education and Research Departments within the 
national office of the ONS in Pittsburgh, PA.  
Survey Design  
An observational design guided the integration of the five recommendations for practice 
change into a descriptive cross-sectional survey that utilized retrospective, self-reported data 
obtained through a web-based questionnaire.  
Survey development: Critical behaviors and supportive processes. No standardized 
tool exists for measuring practice change behaviors and processes aimed at the prevention of 
medication errors or chemotherapy errors. Survey questionnaire content was developed from 
recommended error prevention behaviors and supporting policies and procedures that were 
provided throughout the comprehensive course (See Appendix C). The questions developed were 
based on key national guidelines and practice standards for chemotherapy error prevention, 
specifically found within the ONS Chemotherapy and Biotherapy Guidelines and 
Recommendations for Practice (Polovich et al., 2014) and the 2013 version of the ASCO/ONS 
Chemotherapy Administration Safety Standards (Neuss et al., 2013). 
 Survey development: Barriers to practice change. The Alberta Context Tool (ACT) 
(See Figure B5) is a brief survey tool that addresses eight dimensions of complex care settings 
comprising ten organizational context, or environmental forces, that affect practice behaviors. 
Organizational context is widely considered to be an important contributor to the integration of 
evidence into practice (Squires et al., 2013; Squires et al., 2015). The domains measured by the 
ACT are modifiable and include organizational infrastructure and processes, such as goals, 
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policies, and procedures related to leadership, culture, performance, informal and formal 
interactions, and electronic, human, and space resources (See Table A6) (Squires et al., 2014).  
 The ACT is designed to measure healthcare workers’ perception of how evidence is 
integrated into practice and how the integration is facilitated based on the context of the care 
setting, describing the association between organizational context and reported use of evidence 
in practice (Squires et al., 2014). The psychometric properties of the ACT have been tested since 
2006 in acute care, long-term care, and residential settings using different healthcare 
professionals, including nurses caring for pediatric and adult populations (Estabrooks et al., 
2009; Schultz & Kitson, 2010; Squires et al., 2011; Squires et al., 2013; Squires et al., 2014; 
Squires et al., 2015). Validity assessments of the ACT are considered acceptable based on its use 
in bivariate associations with the ability to discriminate between care settings using factor 
analysis and principal component analysis (Estabrooks et al., 2009; Squires et al., 2014). The 
ACT demonstrated adequate reliability with eight of ten concepts exceeding 0.70 Cronbach’s 
alpha coefficient (Estabrooks et al., 2009; Squires et al., 2014).   
 Some of the organizational context domains of care based on the ACT can be applied to 
chemotherapy error prevention. Therefore, the ACT was used in this project to develop a list of 
potential barriers to both individual and organizational practice change, specifically relating to 
leadership, culture, human resources, structural resource, electronic resources, and informal and 
formal interactions or communication. Table A6 identifies the recommended critical practice 
behaviors and supporting organizational processes within oncology guidelines and practice 
standards for chemotherapy error prevention, and relates them to appropriate ACT organizational 
context domains (Neuss et al., 2013; Polovich et al., 2014; Squires et al., 2014).  
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 Survey content. Qualitative data was collected through self-reported participant 
characteristic, practice behavior, and process change responses. Participants were asked to reflect 
on their practice since course completion. Data demonstrated whether knowledge attained was 
utilized by different nursing groups who work in various chemotherapy care settings to improve 
error prevention strategies that adhere to practice guidelines and standards (see Tables A2 and 
A3). For the purpose of this survey, the definition of chemotherapy included any antineoplastic 
agent used to treat cancer and administered by the intravenous route. Also for the purpose of this 
survey, organizational processes were described as policies, procedures, documentation forms, 
and quality improvement monitoring.  Appendix C provides an electronic copy of the survey 
invitation and content. The survey consisted of seven pages of questions, as described below. 
Survey page one: Participant characteristics. The first page of the electronic survey 
invited respondents to select options that described characteristics of themselves and their 
practice, with the exception of ethnicity and gender, as these were not supported as in the 
literature as factors in applying education to practice (See Appendix C), including: 
 Age; 
 Highest level nursing degree; 
 Professional oncology certification(s); 
 Years of nursing practice, oncology practice, and chemotherapy care; 
 Primary chemotherapy care setting; 
 Primary patient population; 
 U.S. state of practice; and, 
 Month and year of chemotherapy course completion. 
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Survey pages two and three: Critical individual nursing behavior change data collection. 
The second and third pages of the survey addressed critical nursing error prevention behaviors. 
These specific error preventative nursing tasks are components of guidelines and standards 
presented in the course (Neuss et al., 2013; Polovich et al., 2014). These tasks are performed 
during the immediate pretreatment and treatment administration phases (See Appendix C).  
 Page two: Pretreatment error prevention behaviors. Respondents were asked to select 
one of four responses describing their performance of pretreatment critical chemotherapy error 
prevention behaviors since completing the chemotherapy course. The selections indicated the 
participants’ self-perception of each behavior, selecting whether they: 1) consistently performed 
the behavior prior to course completion and no change was needed, 2) sometimes or mostly 
performed the behavior prior to course completion and were now more aware of the need to 
perform it, 3) did not perform the behavior prior to course completion and have since started 
performing the behavior, or 4) did not perform the behavior prior to course completion and still 
do not perform it. The following eleven pretreatment critical chemotherapy error prevention 
behaviors were evaluated (See Appendix C).  
1. Confirm planned treatment education and patient consent for treatment are documented.  
2. Review allergies and current list of all medications for potential interactions.  
3. Verify and document actual patient height and weight.  
4. Ensure and document order completeness by verifying each drug’s name, dose, volume, 
administration route, administration rate, expiration date, and physical appearance.  
5. Ensure and document that two chemotherapy competent staff are engaged in chemotherapy 
order verification process.  
6. Use and document only generic drug names. 
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7. Verify and document dose variations and rationale for each variation.   
8. Verify and document any drug-specific cumulative dose and dose limits.  
9. Verify and document administration sequence of drugs in regimen.  
10. Verify and document correct hazardous drug labeling.  
11. Ensure and document that two individuals verify patient identification.  
Page three: Treatment administration error prevention behaviors. Similarly, respondents 
were asked to select one of the same four responses describing their performance of the 
following four treatment administration critical chemotherapy error prevention behaviors (See 
Appendix C).  
1. Utilize infusion pump to eliminate gravity infusions.  
2. Use infusion set-up with immediate access to primary flush line and emergency equipment. 
3. Assess and document administration site and its appearance. 
4. Assess and document treatment tolerance including any immediate effects. 
Survey page four: Supportive organizational process change data collection. On page 
four of the survey, participants were asked to select one of five responses describing their 
perception of three types of organizational policies and procedures after completing the course. 
The policies and procedures included are general, yet provide systems and unit-based support for 
the nurses’ individual behaviors for chemotherapy error prevention (Neuss et al., 2013; Polovich 
et al., 2014). The response selections indicate knowledge of the existence of policies and 
procedures and whether revisions were started or may still be needed (See Appendix C). 
1. Policies and procedures that support and detail the steps and components needed in the 
pretreatment nursing verification process. 
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2. Policies and procedures that support and detail the steps and components needed in the 
treatment administration process. 
3. Policies and procedures that support and detail nursing pretreatment and treatment 
administration documentation requirements. 
Survey pages five and six: Barriers to change. Components of the Alberta Context Tool 
(ACT) care domains were included in this portion of the survey that assesses for barriers to 
practice and process change. The list of barriers includes challenges in the context of the 
chemotherapy care setting that may affect the initiation of practice change, including 
characteristics, attitudes, and environmental concerns that may indicate concerns related to 
leadership, culture, human and electronic resources, and interactions or communication (Squires 
et al., 2014; Weber & Sidorov, 2014) activities.  
Respondents selected unlimited responses from a list of potential barriers to individual 
practice change and organizational change. The selections reflect challenges that may or may not 
occur when initiating a change related to chemotherapy error prevention. An option to select 
whether no barriers were encountered was also included.  
Page five: Barriers to individual practice change. The following themes or concepts are 
included in the list of nine potential barriers to individual practice change. These were based on 
the known individual factors contributing to chemotherapy errors (see Figure B1) which include 
leadership, human, and electronic resources embedded in the ACT contextual care domains 
(Squires et al., 2014; Weber & Sidorov, 2014) (See Appendix C). 
 Awareness of error prevention strategies, policies, and procedures 
 Adequacy of course content 
 Time constraints 
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 Reluctance to change or speak up 
 Patient engagement in error prevention 
 Professional responsibility for error recognition 
 Use of computerized records 
Page six: Barriers to organizational policy and procedure change. The following themes 
or concepts are included in the list of twelve potential barriers to organizational policy and 
procedure change. These based on the known system and unit-based factors contributing to 
chemotherapy errors (see Figure B1) and include leadership, culture, human and electronic 
resources, and communication/interaction elements within the ACT contextual care domains 
(Squire et al., 2014; Weber & Sidorov, 2014) (See Appendix C).  
 Leadership knowledge, understanding, and receptiveness to change 
 Organizational prioritization of error prevention and best practices for error prevention 
 Communication issues 
 Training and resource issues 
 Staffing and time constraints 
 Electronic system issues 
 Safety culture  
Page seven: Additional information. An option to complete one open-ended question 
was provided at the end of the survey. The question asked, “When providing chemotherapy care, 
please describe what you do differently that helps to identify or prevent chemotherapy errors as a 
result of the knowledge you have attained and guidelines that were provided in the ONS/ONCC 
Chemotherapy Certificate course and accompanying e-book?” (See Appendix C). Data obtained 
in this question will not be analyzed or described in this project. 
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Survey Administration Method and Duration 
The survey was administered through the web-based Zarca Interactive program (2015), 
the established survey program used by ONS. The program allows variability in building a 
survey and various design formats.  Estimated time for completing the survey was verified 
through a pilot administration sent to six clinical nursing staff employed by ONS who met the 
same eligibility as actual survey participants. All reported a completion time between eight and 
nine minutes. Therefore, invitees were told the length of time to complete the survey was 
estimated to be less than 10 minutes. The survey was open for six weeks, and three reminder 
emails were sent.  
Rationale for Project Design 
 Retention of knowledge related to chemotherapy error prevention strategies was already 
established by the participants’ successful completion of the post-test requirement at the 
conclusion of the ONS/ONCC course. The project design was selected based on the existing 
post-program polar (yes-no) evaluation question completed by course participants, in which most 
indicate they intend to use the knowledge gained to improve their practice. Additionally, error 
prevention clarification inquiries are often received by the ONS staff, indicating that practice 
change may be initiated as a result of program content (L. Matey and K. Wiley, personal 
communication, February 19, 2016). The project design provided an initial step in describing a 
relationship between the application of knowledge to initiation of practice and process change, 
with data also used to inform the need for additional educational programming and clinical tool 
development. 
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Data Collection 
Disclosure to Participants 
 The survey began with statements identifying the project purpose, survey objectives, 
expected survey completion time, protection of anonymity during and upon submission of the 
survey, contact email address, and computer requirements.  
Data Access and Tools 
 The DNP student, ONS preceptor, and faculty advisor had access to the survey data 
during the 2016 Autumn and 2017 Spring academic semesters. The student and preceptor were 
involved in data collection. Privacy was assured through the secured ONS database and 
anonymity of the participant data. 
 Participants' responses to each survey item were recorded electronically, and summary 
data was immediately available for review through the Zarca Interactive system. Data was 
downloaded into an Excel spreadsheet and integrated into the Statistical Package for Social Science 
(SPSS) (IBM, 2016; Zarca, 2015). A secure cloud-based system was used for immediate storage 
needs as data was collected and analyzed, which was accessible to the DNP student, preceptor, 
and faculty advisor.  
Data Feasibility  
 Considerations related to the feasibility of this project included approval by ONS 
leadership, and was granted prior to its implementation. Technical issues were considered, such 
as the capability of the survey system, accuracy of email addresses, firewall resistance to receipt 
of the invitation, and the evaluation and customer databases being fully and readily accessible 
during the implementation time. Although not needed, the ONS Information Services department 
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were available to support the project. Additionally, collaboration between the ONS preceptor and 
the DNP student was ongoing. There was no participation incentive offered by the DNP student.  
Reliability and Validity 
The survey content was reviewed, piloted, and validated by five oncology clinical 
specialists who are part of the ONS staff and not involved in course development. Potential 
errors and problems were addressed that included one typographical error and rephrasing of one 
variable. The ONS Information Services staff reviewed the survey from a technical standpoint to 
assure problems related to computer requirements and browser capabilities had been addressed.  
Data Analysis 
Data Entry and Cleaning  
Data cleaning involved inspecting for missing data with data completeness dependent on 
the survey response rate and full completion of the survey questionnaire by participants. No 
surveys were returned incomplete, thus no data were missing. The open-ended question was 
optional, allowing for further discussion of practice-related change.  
Data analysis was performed with SPSS (IBM, 2016). Data analysis included percentages and 
Fisher’s Exact Test to determine relationships between the categorical practice and process 
change variables, including those based on participant characteristics.  Contingency tables were 
used to prioritize the selected variables identified as potential barriers to practice change. 
Collapsing of some participant characteristic variables was performed, including age, 
certification, practice years, and practice settings. A p value of 0.01 was selected due to the large 
number of tests (more than 100) performed for this project. Fisher’s Exact Test was selected 
since many data cells included fewer than five responses, and some included no responses.  
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Section Four 
Findings and Results 
Response Rate 
The project survey invitation (See Appendix C) was sent via email from ONS through the 
Zarca Interactive system to 5,427 eligible participants. There were 372 (6.9%) undeliverable 
messages, resulting in 5,095 receiving and 581 (11.4%) opening the invitation. A total of 334 
completed the survey, representing a response rate of 6.6%. The number of participants that were 
ONS members at the time of the project is unknown. ONS typically receives an 8 to 15% 
response rate for member-based surveys (T. Felice, personal communication, November 10, 
2016). The number of participants that were ONS members at the time of the project was 
unknown. All 50 U.S. states were represented with the five most frequently identified practice 
states being California, New York, Florida, Illinois, and North Carolina (See Table D1). 
Participant Characteristics 
Participant characteristics are detailed in Table D1. There was an equal distribution of 
course dates in which the participants completed the chemotherapy education program. More 
than half (55.4%) of the survey participants were baccalaureate prepared nurses. Credentialing 
with at least one professional oncology certification was reported by 54% of respondents. The 
majority of respondents had four or more years of oncology nursing experience (64%), including 
providing chemotherapy care (60%). Almost all respondents (95%) cared for adults with a nearly 
equal split practicing within inpatient (33.6%) or outpatient (34.2%) oncology settings. 
Critical Individual Nursing Behavior Change Results 
 Fifteen variables are detailed in Appendix C that list individual error prevention 
behaviors, eleven of which are recommended to be performed during pretreatment phase, and 
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four during treatment administration. Course content was considered impactful on practice if 
respondents selected they either, 1) sometimes or mostly performed the behavior prior to 
course completion, and have since become more aware of the need to perform it, or 2) not 
performed the behavior prior to course completion and have since started performing it.  
Pretreatment error prevention behavior change. Two of the eleven pretreatment 
variables outranked the others for having the highest perceived impact on practice (See Table 
D2). These were, 1) verification and documentation of drug-specific cumulative dose or dose 
limits (27%), and 2) use and documentation of only generic drug names (23%). Other 
pretreatment variables perceived as having impact on practice behavior included verification and 
documentation of dose variations (16%), as well as verification of the correct administration 
sequence of drugs within each regimen (11%). About 10% of respondents reported a higher 
awareness to verify and document actual patient height and weight, along with correct hazardous 
drug labeling (See Table D2).  
 Treatment administration error prevention behavior change. The majority of 
respondents endorsed frequent participation in the four treatment administration variables (See 
Table D3). The small subset of respondents who engaged in behavior change indicated 
utilization of an infusion set-up with immediate access to primary flush line and emergency 
equipment was improved (10%).  
Significant Findings in Critical Individual Nursing Behavior Change Results  
 Results that were statistically significant (p< 0.01) based on participant characteristics are 
depicted in Tables D7 and D8. Overall, the most significant differences in course content 
impacting practice was reported between certified and non-certified nurses, with some 
significance noted between inpatient and outpatient nurses.  
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 Certified versus non-certified nurses. All respondents reporting one or more 
professional oncology certifications were considered certified nurses. Statistical significance was 
found in nine of the 15 total individual nursing behavior error prevention variables. Non-certified 
nurses reported the course content had an impact on practice more than certified nurses, and 
certified nurses correspondingly indicated more frequently that their practice did not need to 
change because they already performed the behaviors prior to taking the course.  
Pretreatment error prevention variables. Verifying and documenting drug-specific 
cumulative dose or dose limits showed the largest difference based on participants’ certification 
credentials, with 18% of certified nurses versus 38% of non-certified nurses reporting this 
behavior was impacted by course content (p=0.001). More non-certified nurses reported being 
more aware of the need to perform, or having started to perform, three of the pretreatment 
practice behaviors, including verification and documentation of: 1) actual patient height and 
weight (p=0.005), 2) allergies and current medication list (p<0.001), and, 3) patient education 
and consent for treatment (p=0.010). More non-certified than certified nurses reported having 
increased awareness or performance of the verification and documentation of specific order 
components (p=0.005) and correct hazardous drug labeling (p=0.004). Higher awareness of, or 
practice change that includes, ensuring two individuals verify and document patient 
identification was reported by more non-certified than certified nurses (p<0.001) (See Table D7).  
Treatment administration error prevention variables. The two treatment administration 
behaviors with statistically significant differences between non-certified and certified nurses 
were assessment and documentation of: 1) administration site appearance (p=0.002), and 2) 
treatment tolerance including any immediate effects (p=0.009).  
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 Inpatient versus outpatient nurses. One pretreatment and one treatment administration 
variable demonstrated a statistically significant comparison among nurses providing 
chemotherapy care in inpatient and outpatient settings (See Table D8). Statistical significance 
was associated with a clustering of reported care settings, where inpatient nurses represented 
those working in inpatient oncology along with inpatient non-oncology, intensive care, and BMT 
units. Outpatient nurses included those caring for patients in outpatient oncology clinics and 
infusion centers. Inpatient nurses reported more awareness of the need to perform, or have 
started performing: 1) verification and documentation of drug-specific cumulative dose or dose 
limits (p=0.004), and 2) use of an infusion set-up with immediate access to a primary flush line 
and emergency equipment (p=0.002).  
Significant Findings in Organizational Process Change Results  
 Three questions asked survey participants whether organizational process change was 
initiated since taking the course (See Appendix C). Nearly half of all respondents noted that error 
prevention policies and procedures were already in place without a need for change. The 
majority of the remaining respondents reported initiating conversations with peers and nursing 
leaders to review or revise policies and procedures for pretreatment error prevention (39%), 
treatment administration (37%), and nursing documentation (30%) (See Table D4).  
Significant Findings in Barriers to Change Results 
Survey participants selected one or more statements that reflected their perception of 
barriers encountered or anticipated when initiating individual behavior change and change to 
organizational policies and procedures.  
Barriers to individual practice change. Participants selected one or more statements 
that reflected challenges to change in their personal practice (See Table D5). Almost 40% of 
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participants reported no barriers to their personal practice change. The most frequently cited 
challenge was finding effective strategies to engage patients in error prevention practices 
(31.7%). This was followed by designation of responsibility for order verification (18%), 
resistance to change by nursing colleagues (16.5%), and lack of time to make changes (12%) 
(See Table D5). 
Barriers to organizational policy and procedure change. As with individual practice 
change barriers, nearly the same percentage (40%) of participants selected one or more 
challenges to initiating change to organizational error prevention policies and procedures, 
including documentation forms and quality improvement monitoring (see Table D6). The most 
frequently cited organizational barriers included inadequate staffing and time constraints 
(30.5%), electronic systems that are difficult to change (21%), and lack of ongoing education and 
monitoring related to error prevention (17.7%), policies and procedures not reflecting best 
practices (16.2%), ineffective interprofessional communication (15%), and lack of understanding 
and knowledge of error prevention by organizational leaders (about 15%) (See Table D6).  
 Age of nurses. Responses from different age groups of nurses is most notable in 
perception of barriers to individual practice change (p=0.001) and organizational policy and 
procedure change (p=0.005). For the most part, an inverse correlation was found, showing 
percentages of those perceiving barriers decreasing as age increases (See Table D9).  
 Practice years of nurses. An inverse correlation between practice years and perceived 
barriers to both individual (p=0.005) and organizational (p=0.005) practice was found. As 
practice years increased, the identification of barriers decreased (See Table D9).  
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Discussion 
Several results and findings from this project are notable, and are presented here with 
considerations for interpretation. Regardless of participant characteristics and groupings of 
nurses, the impact of the course on individual error prevention practice behaviors varied greatly 
depending on the specific task being addressed in each survey question. Course content had an 
inconsistent impact on critical individual nursing behaviors during the pretreatment and 
treatment administration. Up to 27% of respondents reported either increased awareness of the 
need to perform a specific behavior, or that they had started to perform a specific behavior since 
taking the course (See Tables D2 and D3). Considerations important to note at the individual and 
systems levels may contribute to the risk for chemotherapy errors as depicted in Figure B1 
(ASCO, 2016; AHRQ, 2016; ASHP, 2015; CCO, 2012; CCO, 2014; Farag et al., 2016; Fyhr et 
al., 2015; Hung et al., 2016; IHI, 2012; IOM, 1999a; IOM, 2013; ISMP, 2016; Keers et al., 2013; 
Kloth, 2010; Lennes et al., 2016; Nelson et al., 2014; Neuss et al., 2013; Neuss et al., 2016; 
Polovich, 2015; Polovich, et al., 2014; Schulmeister, 2006; Schulmeister, 2008; Schwappach & 
Wernli, 2011; Walsh et al., 2009; Warren, 2014; Weber & Sidorov, 2014).  
Impact of the course on individual practice change was noted in both pretreatment and 
treatment administration behaviors.  The increased awareness or initiation of four behaviors (i.e. 
verification and documentation of: 1) drug-specific cumulative dose and dose limits, 2) dose 
variations and their rationale, 3) the sequence of the agents in the regimen, and 4) the use of only 
generic drug names) after the educational program may suggest systems-based issues related to 
the context of care, such as unit-based training, resource availability, and competency evaluation 
processes. Additionally, individual factors to consider include the level of error prevention 
knowledge, self-confidence, and vigilance toward verifying order details to prevent errors (See 
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Figure B1). Treatment administration behaviors may be influenced by external sources rather 
than an individual nurse’s motivation to change. First, the use of an infusion pump and set-up 
that assures access to a primary flush and emergency equipment may vary based on the types of 
treatments being administered in each care setting (intravenous push versus intermittent or 
continuous infusion), and the availability and functionality of infusion equipment (smart versus 
non-smart pump). Secondly, although assessment and documentation of the administration site 
and immediate effects of treatment are behaviors that demonstrate attention to the cyclical 
nursing process and adherence to recommended error prevention strategies, performing these 
behaviors may not be an organizational expectation that is clearly supported by organizational 
policies, procedures, and documentation systems. 
The significant findings related to certified and non-certified nurses were unexpected. 
While certification was not specifically included in the exhaustive literature search methods, 
critical appraisal of the evidence did not identify the attainment of professional certification as a 
strategy or best practice to prevent medication or chemotherapy errors, or as potentially 
impacting practice change following an educational intervention. Of importance to note because 
it has been highlighted in other results, is that the behavior impacted most by the course content 
for both certified (18%) and non-certified nurses (38%) was the need to verify and document 
drug-specific cumulative dose and dose limits during the pretreatment phase. However, non-
certified nurses consistently reported course content had a higher impact on eight other practice 
behaviors than certified nurses, stating course content made them more aware of the need to 
perform, or that they had changed practice and started performing the behaviors (See Table D7). 
Assumptions as to why fewer certified nurses perceived more awareness of, or the need to 
change a behavior, than non-certified nurses may be age and experience, as certification 
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eligibility is partially based on practice experience. Also, certified nurses may have completed 
more oncology-specific education during their certification preparation, providing them with a 
stronger foundation of knowledge related to error prevention. Lastly, a question to consider is if 
higher self-confidence among certified nurses may result in the perception that practice change 
was not needed as often as with non-certified nurses. 
The need to verify and document drug-specific cumulative doses and dose limits during 
the pretreatment phase was cited by a subset of nurses regardless of certification status. 
However, this was a significant notation among the inpatient and outpatient nursing groups. 
Inpatient nurses reported course content gave them a higher awareness of the need to perform, or 
that they started to perform this behavior more frequently than outpatient nurses (See Table D8). 
Although interesting, this may be a logical difference considering the literature recognizes the 
need for effective communication, coordination of care, and integration of electronic systems to 
be in place to accurately translate treatment protocols and summaries between various care 
settings (Brady et al., 2009; Farag et al., 2017; Fyhr et al., 2015; Harris & Northfelt, 2005; Hung 
et al., 2016; McNab et al., 2016; Markert et al., 2009; Nelson et al., 2014; Schwappach & 
Gehring, 2015; Walsh et al., 2013). Having a primary flush line and emergency equipment 
readily available during treatment administration also demonstrated a higher awareness or need 
for change among inpatient nurses. As stated previously, this may correspond to the types of 
treatments being administered, along with varying infusion and emergency equipment 
availability between settings. 
Two project outcomes deserve meaningful consideration, although not statistically 
significant. Overall, a high percentage of responses indicated no perceived need to change 
because specific behaviors were already being performed (See Tables D2 and D3). More than 
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70% of respondents reported this for eight of the eleven pretreatment behaviors, and more than 
75% reported already performing the four treatment administration behaviors. This suggests 
many individual nurses were already knowledgeable about error prevention strategies and apply 
them to daily practice. Conversely, a subset of respondents indicated they did not perform 
specific behaviors prior to or upon completion of the course (See Tables D2 and D3). As such, 
this may be an area which course developers review to enhance future course content.   
Barriers to initiating practice change are crucial to note at this point, and may affect 
perceived impact of the course content (Melnyk, 2012; Melnyk & Fineout-Overholt, 2015; 
Melnyk, Fineout-Overholt, Gallagher-Ford, & Stillwell, 2011; Melnyk et al., 2017; Squires et al., 
2014). More than 60% of participants reported encountering or anticipating at least one challenge 
when initiating change in their own practice (See Table D5). This may suggest the practice 
implementation barrier prevented change from being reported in the survey, so the nurse reported 
more awareness of the need to perform a behavior because of the challenge. Patient engagement 
in error prevention was ranked as the biggest challenge, correlating with some of the literature 
review citing the need to assure patients are partners in safety, as well as the newly established 
reporting requirements that demonstrate patient-centric care is being delivered (Etchegaray et al., 
2016; Harris et al., 2014; Kullberg et al., 2013; Nelson et al., 2014; Schulmeister, 2008; 
Schwappach et al., 2010; Schwappach & Wernli, 2011; Shojania et al., 2001).  
Professional accountability of the nurse may be a concern, as it was the second highest 
ranked barrier with some nurses believing the physician and pharmacist are primarily responsible 
for error prevention. The third highest barrier was that nurse colleagues may question the 
necessity of practice change recommendations based on course content. The latter may relate to 
the need for personal empowerment among younger or less experienced nurses, with evidence 
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suggesting that errors are affected by practice experience and incivility issues among nursing 
peers (AHRQ, 2016; Fyhr et al., 2015; Harris & Northfelt, 2005; Hung et al., 2016; McNab et 
al., 2016). Lastly, time constraints as a barrier to individual practice change is supported in the 
literature, and may reflect ineffective personal time management or workload and staffing 
((Harris & Northfelt, 2005; Prakash et al., 2014; Trbovich et al., 2010; Walsh et al., 2013). 
At least 30% of respondents reported starting discussions at their institutions upon 
recognizing the need to review or revise organizational error prevention policies and procedures 
based on course content (See Table D4). While this outcome may indicate the course content had 
an impact on organizational change, it also suggests a priority patient safety through practice 
change was demonstrated by one-third of the individual nurse participants who initiated the 
conversations. Policies and procedures as drivers to support error prevention through 
recommended pretreatment and treatment administration behaviors were most frequently 
addressed in these conversations with nursing peers, managers, and leaders.  
Barriers to organizational change are key project outcomes to consider. Again, more than 
60% of participants reported at least one challenge was encountered or anticipated in initiating 
change at the organizational level. Time and staffing were selected as the most identified barrier, 
and are noted as clear prohibitive factors to the change process within the literature (AHRQ, 
2016; Farag et al., 2016; Fyhr et al., 2015; Hung et al., 2016; IHI, 2012; IOM, 2013; Keers et al., 
2013; Lennes et al., 2016; Nelson et al., 2014; Polovich, 2015; Schulmeister, 2008; Schwappach 
& Wernli, 2011; Walsh et al., 2009). Also supported in the literature is the need for electronic 
systems that are easily adaptable, and electronic systems being difficult to change were the 
second highest ranking barrier to organizational change (Bourmaud et al., 2014; Cheng et al., 
2012; Dobish et al., 2016; Gandhi et al., 2005; ISMP, 2016; Jia et al., 2016; Kullberg, et al., 
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2013; Nerich, et al., 2010; Rodriguez, 2016; Ranchon et al. 2011; Walsh et al., 2013; Watts & 
Parsons, 2013; Weingart et al., 2010). Organizational culture is the theme in the remainder of the 
most selected barriers, including lack of ongoing training and monitoring for errors, policies and 
procedures that do not support best practices in error prevention, poor interprofessional 
communication, and lack of leaders’ understanding and knowledge of error prevention.  
Conclusions 
The prevention of chemotherapy errors and provision of comprehensive chemotherapy 
education are recognized priorities in cancer care settings. The purpose of this project was to 
assess the impact of knowledge attained from a comprehensive chemotherapy course on 
individual nursing behaviors and organizational processes that are compliant with evidence-
based chemotherapy error prevention strategies. This program evaluation was an initial step in 
describing a correlation between the application of knowledge to practice through behaviors that 
promote chemotherapy error prevention.  
Overall Survey Themes 
Conclusions are presented as they relate to the three overall survey themes (See Section 
Three). The project survey content covered three themes that explored nurse participants’ post-
program perceptions relating to error prevention and considered the need for, initiation of, and 
barriers to individual and organizational change (See page 30 and Table A5). Certified nurses 
were less likely to perceive a need for practice change than non-certified nurses. Regardless of 
age, practice experience, work setting, or certification, the two critical individual nursing 
behaviors most significantly impacted overall by course content were verifying and documenting 
drug-specific dose limits and cumulative doses, and the use and documentation of only generic 
drug names (See Tables D2 and D3). The course also had an impact on organizational process 
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change, with more than one-third of the respondents initiating conversations with nursing peers 
and leaders to improve organizational error prevention processes, specifically policies and 
procedures that support their individual behaviors (See Table D4).  
Respondents encountered or anticipated challenges to individual practice change and 
organizational process change that correspond to the literature and recent trends in the oncology 
environment. The most notable barriers to individual practice change were needing better patient 
engagement in error prevention, lack of professional accountability for preventing errors, and 
potential nursing incivility. Challenges to initiating organizational process change primarily 
indicate underlying factors associated with system structures and unit level context of care, such 
as ineffective leadership, failure to prioritize safety goals and processes, inadequate resources, 
and poor communication (See Tables D7 and D8).   
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Section Five 
Project Summary 
This project assessed how the ONS/ONCC Chemotherapy and Biotherapy Certificate 
course may impact individual and organizational practice specific to error prevention strategies. 
An observational design methodology guided the project consisting of a descriptive cross-
sectional survey that utilized retrospective, self-reported data obtained from 334 registered 
nurses through a web-based questionnaire. Survey content was developed based on 15 
recommended individual critical behaviors and their supporting organizational processes for 
chemotherapy error prevention interspersed in practice guidelines and standards. The survey 
content covered three themes that explored nurse participants’ post-program perceptions of the 
need for, initiation of, and barriers to individual and organizational change for error prevention. 
Impact on practice was considered to have occurred if course participants developed more 
awareness of the need to perform specific behaviors, or changed practice to better integrate error 
prevention strategies at the individual and organizational levels. This program evaluation was an 
initial step in describing a correlation between the application of knowledge to practice through 
behaviors that promote chemotherapy error prevention.  
Limitations 
Limitations of this project include the low survey response rate of 6.6%. ONS typically 
receives a response rate between 8 and 15% for member-based surveys. The lower response rate 
may be attributed to the fact that less than half of registered participants in the ONS/ONCC 
Chemotherapy and Biotherapy Certificate course were ONS members. Non-members may not be 
accustomed to receiving ONS emails or may not consider opening emails received from ONS 
compared to members. The survey was also conducted in the six weeks prior to the Thanksgiving 
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and December holiday season, therefore competing with many life events. Another limitation 
relates to practice characteristics, with almost all respondents providing chemotherapy care to 
adults and only 6% working in a BMT setting. Nurses in pediatric hematology/oncology and 
BMT settings administer antineoplastic agents quite frequently. Therefore, this sample may not 
adequately represent all nurses delivering chemotherapy care.  
Lastly, this project collected retrospective, self-reported data and asked participants to 
reflect on how course content impacted practice in the six to twelve months since completing the 
course. Recall problems and response bias may occur in survey participants. These may be due 
to the length of time since the course was completed, and if the nurse reports more or less 
behavior change than actually occurred (Stommel & Wills, 2004).  
Implications for Practice 
The outcomes of this project assist in understanding the educational and supportive needs 
of nurses who provide chemotherapy care, specifically related to implementing error preventive 
strategies into practice behaviors, policies, and procedures. The data analysis outcomes were 
integrated into the three project survey themes in Section Four, and support the EBP process 
described in the ARCC Model through the five evidence-based recommendations for practice 
change presented in Section Three. Additionally, this project demonstrates alignment with the 
Doctor of Nursing Practice (DNP) Essentials (AACN, 2006). 
Recommendations for Practice Change 
Recommendation One: Provide comprehensive chemotherapy education for nurses. 
This project assessed just one area of content interspersed throughout the ONS/ONCC 
Chemotherapy and Biotherapy Certificate course. Project outcomes describe the impact of 
educational content on error prevention at both the individual and organizational levels, and 
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ongoing education and competency assessments are considered best practices in error prevention. 
Certification preparation resources may enhance the performance of critical nursing behaviors 
for error prevention. Barriers to implementing safety practices may need more attention within 
the course. Collaboratively reviewing course content with error prevention and EBP subject 
matter experts may strengthen the program with inclusion of professional practice strategies for 
implementing behaviors and overcoming barriers to change. 
Recommendation Two: Integrate practice guidelines and standards. Evidence-based 
error prevention practices included in the ONS/ONCC course content are grounded in guidelines 
and standards that address both individual practice behaviors and organizational processes. 
However, the 15 critical individual nursing behaviors identified and used in this project were not 
found in one cohesive grouping, but rather fragmentally identified within guidelines, standards, 
and the content of the course. Project outcomes suggest that while the critical best practices are 
widely available, they are not always included in policies and procedures or may be missing 
completely. Rethinking the presentation and dissemination of best practices for error prevention, 
and utilizing EBP champions to assess readiness for change through review of policies and 
procedures, and further exploration of barriers to implementation may be a beneficial approach.  
Recommendation Three: Assess practice change needs related to critical behaviors. 
Project outcomes propose that most nurses are already practicing all except two of the critical 
individual behaviors; however, all 15 recommended behaviors should be implemented to 
optimize patient safety and demonstrate accountability for error prevention. The presence of 
barriers to practice change reported by 60% of respondents suggests nurses may benefit from 
strategies to enhance personal and professional empowerment.  A strong interprofessional 
statement or report of the need to include the 15 behaviors in practice may reinforce their 
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integration into practice. This statement or report, along with a better organized presentation and 
dissemination of recommended critical individual nursing behaviors may assist EBP champions 
to more effectively demonstrate a change is needed. 
Recommendation Four: Implement organizational processes to support practice 
change. Practice change adoption in individuals may not correspond to readiness to change 
within the workplace culture and context of care. Project outcomes indicate more than 30% of 
respondents identified a need to initiate review or revision of organizational error prevention 
policies and procedures. And, more than 60% of participants encountered or anticipated at least 
one barrier to making those organizational changes. Again, a strong interprofessional statement 
or report may help EBP champions to elevate organizational understanding of the connection 
between effective implementation of evidence-based error prevention strategies and improved 
patient outcomes.  
Recommendation Five: Prioritize a culture of safety. The intent to list the 
recommendation to prioritize safety late is purposeful. This recommendation is, by far, the most 
important because it provides the foundation for effective chemotherapy error prevention. Project 
outcomes describe a need for champions to advocate for a safe and just culture, with 60% of 
survey respondents identifying one or more barriers to implementing a change that is aimed at 
preventing chemotherapy errors and improving patient safety outcomes. Without a true culture of 
safety, the 15 critical individual error preventive nursing behaviors cannot be fully supported or 
effectively implemented, even if strong organizational processes, policies, and procedures exist. 
A culture of safety involves a commitment to prioritizing safety goals over all else. This includes 
error prevention, recognition, and reporting that transcends through all levels and is 
demonstrated within all disciplines. 
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The results also help to determine the effectiveness of current chemotherapy 
programming, enhance future offerings, develop tools to assist with guideline and EBP 
implementation processes, and establish ongoing practice change data collection to further 
impact the quality of chemotherapy care.  
Alignment with the Doctor of Nursing Practice Essentials 
 The Essentials of Doctoral Education for Advanced Practice Nursing (AACN, 2006) 
provide guidance for Doctor of Nursing Practice (DNP) program curriculum, and delineate the 
competencies of a nurse holding the DNP credential. The eight DNP Essentials are integrated 
and demonstrated in the final DNP scholarly project (Moran, Burson, & Conrad, 2014). “Rather 
than a knowledge-generating research effort, the student in a practice-focused program generally 
carries out a practice application-oriented final DNP project” (AACN, 2006, p. 3). This DNP 
project demonstrates practice scholarship by exploring a clinical practice problem, and guiding 
the translation of evidence-based knowledge into practice for improved patient safety (AACN, 
2015; Moran et al., 2014). This project aligns with the DNP Essentials as described below.  
DNP Essential I: Scientific Underpinnings for Practice  
DNP Essential I addresses the use of evidence-based literature and theories, models, or 
frameworks aimed to improve practice outcomes. These supporting elements demonstrate 
whether an intervention may correlate with changes that promote implementing evidence-based 
care and decision-making (AACN, 2015; Moran et al., 2014). Relating Essential I to this project, 
medication errors may have significant impact on care delivery; interventions to reduce errors 
and continually evaluate outcomes are grounded in evidence-based guidelines and standards 
(AACN, 2006, p. 9). This project assesses nurses’ perception of practice change specific to error 
prevention following educational programming. The survey content reflects evidence-based 
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strategies found within practice guidelines and standards, and presented in a comprehensive 
chemotherapy course. Additionally, the use of two science-based frameworks and a model for 
implementing evidence into practice guided development of the survey content of this project. 
DNP Essential II: Organizational and Systems Leadership for Quality Improvement and 
Systems Thinking  
 DNP Essential II implies the ability to collaboratively identify and address emerging 
practice problems to improve the quality of care at all levels within the organization (AACN, 
2015; Moran et al., 2014). Specific to this project, a critical safety need for a specific patient 
population is identified and the impact of one evidence-based intervention for improvement is 
deeply explored (AACN, 2006, p. 10). This project explores chemotherapy errors as a 
multifactorial variance and quality improvement priority with interdisciplinary accountability. 
Sustainable structural and unit-based processes as well as individual behaviors that address error 
recognition and reporting are explained and integrated throughout the project. This project 
particularly describes perceptions and challenges faced by nurses that may impact practice 
change and patient safety through error prevention.  
DNP Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based 
Practice 
 DNP Essential III refers to the application critical analysis and thinking processes. Best 
practices are determined by critically appraising the existing evidence. In addition, evaluating 
programs and processes to assess their impact on practice is key to Essential III (AACN, 2006, p. 
12; AACN, 2015). Specific to this project, determining the impact of chemotherapy education on 
nursing practice to prevent errors is the goal.  Existing educational processes and content, 
practice guidelines and standards, and evidence from various studies are appraised and applied 
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within the project. More specifically, this project seeks to know the impact of education on the 
application of critical behaviors supporting processes within the practice environment.  
DNP Essential IV: Information Systems/Technology and Patient Care Technology for the 
Improvement and Transformation of Health Care  
 DNP Essential IV relates to the application of information systems and technology to 
evaluate care outcomes (AACN, 2006, p. 12; AACN, 2015). This project aligns with Essential 
IV in multiple ways. Firstly, this project uses a web-based survey to assess the impact of a 
chemotherapy education program delivered through an online learning management system. 
Secondly, strategies for error prevention are explored that include electronic and computerized 
ordering and documentation, decision supports, and smart infusion pumps. Thirdly, variables 
within the project survey include the use of appropriate patient care equipment and infusion set-
ups that are components of recommended chemotherapy error prevention strategies. Lastly, this 
project encompasses potential barriers related to the use of technology that can facilitate the 
understanding of the nurse’s role in error recognition to improve outcomes.  
DNP Essential V: Health Care Policy for Advocacy in Health Care  
 DNP Essential V addresses advocating for healthcare policy, including structures and 
processes that guide professional standards development and institutional decision making 
(AACN, 2006, p. 14; AACN, 2015; Moran et al., 2014). Safety training, the use of evidence-
based knowledge, and outcome reporting are integral parts of professional practice standards, as 
well as regulatory accreditation agencies, reimbursement stipulations, and health policy 
legislative criteria. The failure to prevent errors leads to ethical dilemmas that weaken 
confidence in clinical judgment, increase risk for harm, and erode patient-provider trust. This 
project identifies a critical safety issue in the oncology environment, critically analyzing 
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standards related to mitigating the risk of chemotherapy errors. The project advocates for 
patients, nurses, and organizational leaders by exploring best practices for error prevention and 
conducting a program evaluation that assesses the impact of education on practice change.  
DNP Essential VI: Interprofessional Collaboration for Improving Patient and Population 
Health Outcomes 
 DNP Essential VI addresses effective communication and collaboration among various 
disciplines (AACN, 2015; Moran et al., 2014). Specific to medication errors, a collaborative, 
multidisciplinary systems approach is essential to develop a culture that cultivates practice 
excellence and prioritizes safety. The need for establishing interprofessional and individual 
accountability in error prevention is stated throughout the stages of this project. This project 
describes the complexities involved in the chemotherapy planning and administration process 
from an interprofessional standpoint, while focusing on the potential impact of education as an 
error prevention strategy.  
DNP Essential VII: Clinical Prevention and Population Health for Improving the Nation’s 
Health  
DNP Essential VII delineates the need for clinical prevention through health promotion  
and risk reduction. This may involve a deep look into a specific aggregate population, such as 
people with cancer who are receiving antineoplastic agents (AACN, 2006, pp. 14-15; AACN, 
2015).  Due to the hazardous nature of many of these drugs and the common presence of 
comorbid conditions, overdosing and underdosing may result in patient harm. Specific to this 
project, data is analyzed that include the implementation and evaluation of interventions to 
improve outcomes through error prevention. This project seeks to improve the health of a 
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specific patient population through error prevention, and explores the integration of, and barriers 
to, applying education to nursing practice and organizational policies and procedures.  
DNP Essential VIII: Advanced Nursing Practice 
 DNP Essential VIII addresses the highest level of nursing practice through expertise,  
advanced knowledge, and specialization. This competency emphasizes the demonstration of 
clinical judgment and accountability, including the design, implementation, and evaluation of 
interventions based on critical appraisal of all levels of evidence that support the nursing 
profession and facilitate optimal practice outcomes (AACN, 2006, pp. 16-17; AACN, 2015). 
This project shows alignment with Essential VIII by evaluating the impact of an educational 
program that teaches foundational safety practices and error preventive strategies. The clinical 
problem of chemotherapy errors necessitates that educational needs of nurses are met with 
knowledge that is easily translated into practice. Chemotherapy nurses must possess the skills 
and confidence to provide care that optimizes patient and staff safety. Additionally, 
organizational processes and clinical tools need to be sufficient to support the integration of error 
prevention strategies into practice. This project seeks to identify individual and organizational 
change impacted by the integration of knowledge to practice, and barriers to initiating change. 
This project makes a connection between practice, organizational, accreditation, and policy 
issues related to medication errors specific to the oncology environment. 
Project Dissemination 
Dissemination of the outcomes of this project are of interest to a variety of nursing 
leaders, patient safety professionals and advocates, professional oncology associations, and QI 
and EBP professionals.  
 
ASSESSING THE IMPACT OF CHEMOTHERAPY EDUCATION 73 
Potential Audiences 
Executive leaders, clinical nurse leaders and managers, staff educators, and clinical nurse 
specialists may find the outcomes relate to their patient safety goals, and can be utilized to 
review and potentially improve error prevention strategies within practice settings where 
chemotherapy care is delivered to assure best practices are implemented. The same executive and 
clinical leaders may want to assess the safety culture of their environments to better prioritize 
pharmacovigilance and safety related to high-risk medication ordering and administration. 
Organizations with an interest in attaining or maintaining Magnet recognition status, as 
well as nurse credentialing agencies, such as ONCC and the American Nurses Credentialing 
Center (ANCC), may be curious to learn about the practice change data differences between 
certified and non-certified nurses. Professional oncology associations, such as ASCO, ONS, and 
the Advanced Practitioner Society for Hematology and Oncology (APSHO) may be interested in 
learning how nurses utilize error prevention strategies in practice that are based on accepted 
practice guidelines and standards. These same professional organizations can utilize the findings 
to promote and improve chemotherapy education for nurses and other healthcare professionals.  
Lastly, health policy and regulatory agencies interested in patient safety outcomes may recognize 
the importance of practice change and error prevention implementation strategies. 
Methods of Dissemination 
 The project background, purpose, description, and outcomes have been submitted and 
accepted at two professional nursing conferences as poster presentations in May, 2017. A third 
abstract has been submitted for possible presentation at an EBP conference in October, 2017. A 
manuscript is being prepared to submit for publication in a peer-reviewed oncology journal by 
June, 2017. Additionally, some data collected through the survey is not considered central to the 
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topic or project purpose. Further analysis of this supplemental data will be performed, with 
possible submission for publication later in 2017. 
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Appendix A: Evidence and Descriptive Tables 
Tables A1, A2, A3, A4, A5, A6  
 
Table 1 
Synthesis of Studies to Determine the Incidence of Chemotherapy Errors  
Citation Type of Study Percent (%) Incidence of Chemotherapy 
Gandhi et al., 2005 Prospective cohort study 3.0% (n = 10,112) 
Ford et al., 2006 Prospective study 0.04% (n = 4680) 
Retrospective record review following prospective study 0.02% (n = 200) 
Markert, et al., 2009 Prospective descriptive study 3.8% - 4.5% (n  = 22,216) 
Ranchon et al., 2011 Prospective study 5.2% (n = 6,607) 
 
Note. Percent incidence of chemotherapy errors based on number of orders reviewed.  
n = number of chemotherapy orders reviewed 
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Table 2 
Evaluation and Synthesis of Reports, Standards, and Guidelines Related to Medication and Chemotherapy Errors 
Citation  
and/or 
Expert Committee 
Design 
and/or 
Methods 
Topic of Interest 
or  
Clinical Problem 
Data Analysis Findings  
and 
Recommendations 
Level  
and 
Quality of Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                               
IOM, 1999a Expert report; 
systematic review  
Quality cancer care Synthesis of evidence; 
expert consensus 
Tables A4 and 5; 
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
IOM, 1999b Expert report; 
systematic review  
Medical errors Synthesis of evidence; 
expert consensus 
Tables A4 and 5; 
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
IOM, 2001 Expert  report; 
systematic review  
Healthcare quality Synthesis of evidence; 
expert consensus 
Tables A4 and 5; 
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
Shojania et al., 2001 Expert report; 
systematic review  
Healthcare safety  Synthesis of evidence; 
expert consensus  
Tables A4 and 5; 
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
IOM, 2003 Expert report; 
systematic review  
Patient safety; nursing work 
environment 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5; 
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
IOM, 2004 Expert report; 
systematic review  
Patient safety standards Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
11; high; significant evidence  supporting 
recommendations for error prevention 
IOM, 2006 Expert report; 
systematic review  
Preventing medical errors Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
Kloth, 2010 CPG; systematic 
review  
Preventing chemotherapy 
errors 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
IHI, 2012 CPG; systematic 
review  
Preventing harm from high-
alert medications 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
CCO, 2012 CPG; systematic 
review  
Safe chemotherapy 
administration; part 1 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
IOM, 2013 Expert report; 
systematic review  
Quality cancer care; follow up 
to IOM, 1999a 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
Shekelle et al., 2013 Expert report; 
systematic review  
Healthcare safety; follow up to 
Shojania et al., 2012 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
Neuss et al., 2013 Practice standard; 
systematic review  
Chemotherapy administration 
safety standards 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
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Citation  
and/or 
Expert Committee 
Design 
and/or 
Methods 
Topic of Interest 
or  
Clinical Problem 
Data Analysis Findings  
and 
Recommendations 
Level  
and 
Quality of Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                               
CCO, 2014 CPG; systematic 
review  
Safe chemotherapy 
administration; part 2 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
ASCO, 2016 CPG; systematic 
review  
State of cancer care Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
Polovich et al., 2014 Guidelines; 
systematic review  
Chemotherapy guidelines and 
recommendations 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
ASHP, 2015 CPG; systematic 
review  
Preventing chemotherapy 
errors 
Synthesis of evidence; 
expert consensus 
Tables A4 and 5;  
Figure B4 
1; high; significant evidence supporting 
recommendations for error prevention 
  
Note. Publications are listed chronologically to show progression of attention to the clinical issue. Levels of evidence for CPGs and reports are based on the 
rating system for the hierarchy of evidence for intervention/treatment questions (Melnyk & Fineout-Overholt, 2015, p. 11). Additional considerations for the 
quality of evidence for CPGs are based on the IOM eight standards for developing trustworthy guidelines (IOM, 2011). 
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Table 3 
Evaluation and Synthesis of Additional Supporting Literature Related to Medication and Chemotherapy Errors 
Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
Keers et al., 
2013 
 
 
 
 
 
 
 
 
Brady et al., 
2009 
Reason’s 
model of 
accident 
causation 
 
 
 
Human error 
models 
Systematic review 
 
 
 
 
 
Systematic review 
54 studies with 
data on inpatient 
medication errors; 
chart review and 
direct observation  
 
 
 
26 peer-reviewed 
qualitative and 
quantitative 
studies 
Determine 
causation factors 
for medication 
administration error 
and near miss data 
 
 
 
Determine 
contributing 
factors to 
medication errors 
Perceived 
responsibility  
for medication 
preparation and 
dispensing errors 
 
 
 
-Knowledge, 
skill, level, 
workload, 
distractions of 
nurses 
-Processes for 
drug dispensing 
and error 
reporting 
Percentages 
 
 
 
 
 
 
No stats 
-Individual causes for error 
related to knowledge and 
rule based mistakes: 
53.7%;  
-Environmental and 
structural conditions 
including policies and 
procedures: 31.7% 
 
-Findings: Most common 
contributor to errors: nurse 
drug knowledge, 
dispensing process, quality 
of orders; deviation from 
standard dosing; nurse 
distraction; excessive 
workload 
-Recommendations: 
Assurance of consistency 
of error reporting; ongoing 
competency assessment 
for nurses; standardize 
error reporting process 
through healthcare policy 
initiation, local outcomes 
evaluation 
 
5; moderate to 
high; supports 
known 
contributors to 
error  
 
 
 
5; moderate to 
high; supports 
known 
contributors to 
error and 
resulting 
strategies for 
error 
recognition, 
reporting, and 
reduction 
Smeulers et 
al., 2015 
None Systematic 
review; PRISMA  
5 qualitative 
studies 
Assess specific 
structure, process, 
and outcome 
quality indicators 
pertaining to safe 
medication use 
21 quality 
indicators for 
medication 
management 
Quality 
indicator 
sets; AIRE 
instrument 
tool 
-Recommendations: 
Further development of 
quality indicators 
addressing nursing, 
specific to patient 
identification, route 
verification, appropriate 
documentation 
5; moderate to 
high; quality 
indicators to 
support 
strategies for 
error 
recognition, 
reporting, and 
reduction 
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Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
Weingart         
et al., 2010 
None Systematic review 
including disparate 
database review 
508 reported oral 
chemotherapy  
events 
Determine types       
of chemotherapy 
errors 
-Type of error     
-Phase in 
medication use 
process of error 
occurrence  
Interrater 
reliability; 
percentages 
-Findings: Similar types    
and phases of error 
occurrence as with other 
types of chemotherapy  
-Recommendations:  
Standardize oral treatment 
ordering and monitoring 
processes  
5; moderate to 
high; supports 
known 
contributors to 
error and resulting 
strategies for error 
reporting and 
reduction 
 
Kullberg         
et al., 2013 
None Literature review; 
descriptive and 
qualitative studies 
12 studies reviewed Explore interventions 
to reduce 
chemotherapy errors 
Consistency of   
five specific 
interventions in 
reducing error 
No stats -Findings: CPOE  
consistently safer than 
handwritten orders; other 
interventions helped to 
improve patient safety 
-Recommendation: More 
studies about  using FMEA, 
error reporting systems, 
administration checklist, 
nursing education 
5; moderate; good 
composite of 
literature review; 
background 
information on 
specific 
documentation;  
supports strategies 
for error 
recognition,  
reporting, and 
reduction 
 
Schwappach   
& Wernli, 
2010 
None Literature review 112 studies Explore patient 
willingness to be 
involved in error 
prevention activities 
Strategies to engage 
patients in error 
prevention 
No stats -Recommendations:   
Ongoing motivation and 
reiteration of importance      
of patient engagement; use 
simple rule-based 
instructions; perform 
verification together; explain 
device alarms; ongoing 
teaching; continuous request 
of patient status info 
5; moderate to 
high; supports 
strategies for error 
recognition, 
reporting, and 
reduction 
Baldwin & 
Rodriguez, 
2016 
None Retrospective, 
descriptive study; 
RISQ database 
4,282 events; error 
database inquiry; 5 
years 
Describe importance 
of chemotherapy 
verification nurse in 
identifying 
prescribing errors 
Roles of 
verification nurse 
No stats; 
percentages 
and anecdotal 
data 
-Findings: 506 of 4282 events 
occurred after verification 
nurse involvement (0.07%), 
most during administration 
causing no patient harm; 
majority near-miss events, 
induced no patient harm, or 
5; moderate; no 
stats reported on 
errors before 
verification nurse 
involvement; 
supports important 
standards 
ASSESSING THE IMPACT OF CHEMOTHERAPY EDUCATION     102 
Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
identified at the point of 
prescribing   
-Recommendation: Value of 
verification nurse is high with 
comprehensive review of 
order for completeness, 
accuracy/appropriateness  
inclusion of 
strategy for error 
recognition and 
reduction 
Markert et al., 
2009 
None Prospective cohort 
study 
22,216 
chemotherapy 
orders; inpatient and 
outpatient oncology; 
2 years 
Assess the 
effectiveness of a 
chemotherapy 
surveillance team in 
preventing medication 
errors 
Number and types 
of chemotherapy 
errors; error 
interception rate 
No stats; 
percentages 
reported 
-Findings: 3,792 errors in   
22,216 orders, most 
administrative; 3 errors 
reaching the patient for 
99.9% error interception rate 
-Recommendation: Consider 
use of multiple check 
interprofessional 
chemotherapy order 
surveillance team 
6; moderate; 
supports strategy 
for error 
recognition 
Robinson, et 
al., 2006 
FMEA Prospective QI 
study; 
preimplementation 
and 12 months 
postimplementation  
331 records pre and 
221 medical records 
post; hospitalized 
children with cancer; 
acute care 
Determine error 
prevention and 
reporting behaviors 
pre and post 
preprinted order sets 
and CPOE 
implementation 
-Error reporting pre 
and post 
-Error reduction pre 
and post 
No stats; 
percentages 
reported 
-Findings: Error reduction by 
40%; actual administration 
error report reduction of 25% 
-Recommendations: 
Implement preprinted order 
sheets and CPOE 
6; moderate; 
supports strategies 
for error reporting 
and reduction 
Cheng et al., 
2012 
FMEA Prospective QI 
study; 
preimplementation 
and 12 months 
postimplementation 
22,250 
chemotherapy 
orders; inpatient and 
outpatient  
Determine effect of 
integrating CPOE on 
error reduction 
-Error reduction pre 
and post 
Chi-square; 
percentages 
-Finding: Error reduction 
from 3.34% to 0.40% (p = 
0.04) 
-Recommendations: Use 
FMEA to evaluate safety 
risks; implement CPOE 
6; moderate; 
supports strategy 
for error reduction 
Looper et al. 
2015 
SBAR; PDCA Prospective QI 
study; 
preimplementation 
and 6 months 
postimplementation 
48 cancer centers; 
282 medical records; 
pediatric patients; 
inpatient and 
outpatient 
Determine 
compliance with 
implementation and 
use of standardized 
and safe 
chemotherapy 
Use of and 
compliance with 
guidelines and 
standards for safe 
chemotherapy 
administration 
No stats; 
percentages 
reported 
-Finding: Compliance with 
standards 100% in 6 months 
-Recommendation: 
Standardize processes for safe  
administration; order 
verification for sequence and 
6; high; shows 
effectiveness of 
implementing 
multiple care 
standardizations in 
various settings 
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Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
administration 
techniques 
exact administration times 
imperative; use consistent 
parameters for documentation 
         
Walsh et al., 
2009 
None Retrospective QI 
study; record review 
1,262 adult cancer 
patients with 10,995 
medication 
administrations; 117 
pediatric cancer 
patients with 913 
medication 
administrations; 3 
adult clinics; 1 
pediatric clinic; 4 
different states 
Determine rates and 
type of medication 
errors and system 
factors associated 
with errors 
-Error rates 
-Error types 
-System based 
factors contributing 
to errors 
Cronbach’s 
alpha 
-Findings: 112 errors 
including clinic and home 
self-administration errors; 
7.1% (adult), 18.8% 
(pediatric); 64 of 112 
potential to cause harm;       
15 of 112 resulted in injury; 
56% error during 
administration phase;  
-Recommendations: CPOE; 
physician order reviewers to 
improve communication 
6; high; verifies 
nurse as key 
contributor to 
error prevention; 
supports known 
contributors to 
error and resulting 
strategies for error 
recognition and 
reporting 
Walsh et al., 
2013 
None Prospective 
observational  
study; interview  
and observation 
242 medication 
administrations; 
pediatric cancer 
patients; in-home 
care 
Determine frequency 
of and strategies to 
reduce preventable 
medication errors 
including 
chemotherapy and 
supportive care drugs 
-Error occurrences 
-Patient/family 
involvement  
-Patient education 
-Communication 
processes 
Interrater 
reliability; 
percentages 
-Findings: Errors related to 
either oral chemotherapy or 
supportive care agents caused 
harm in 3.6 per 100 patients 
(95% CI: 1.7-5.5); errors with 
potential to cause harm in 
36.3 per 100 patients (95% 
CI: 29.3-43.3)  
-Recommendation: Improve 
and standardize care 
transition communication, 
patient education, compliance 
monitoring 
6; moderate to 
high; supports 
known 
contributors to 
error and resulting 
strategies for error 
recognition and 
reporting 
Nelson et al., 
2014 
None Policy development; 
literature review 
Unspecified 
oncology setting 
Develop proactive 
policy and procedure 
to ensure rapid 
response to accidental 
chemotherapy 
overdose 
Optimize 
chemotherapy 
dosing safety 
No stats; 
anecdoctal 
process  
-Recommendations: Establish 
practice guidelines 
facilitating early recognition 
and immediate action to 
chemotherapy overdose; 
identify potential 
interventions and assess-
ments to promote safety; 
educate patients and family 
regarding treatment plan and 
6; moderate; 
evidence and 
recommendations 
to support error 
recognition and 
reporting 
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Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
required monitoring 
 
Schwappach   
et al., 2010 
None Qualitative 
descriptive study; 
focus groups; 
complement study 
to Schwappach & 
Wernli, 2010 
11 oncology nurses; 
inpatient and 
outpatient oncology 
Explore nurses’ 
perception of patient 
involvement in error 
prevention 
Four themes: 
involving patients; 
challenges and 
barriers; 
responsibility for 
safety; learning and 
reflecting 
No stats; 
percentages 
and anecdotal 
reports 
-Findings: Affirmative 
attitudes and positive 
experiences engaging patients 
yet challenging; engagement 
improved trust and 
confidence in care  
-Recommendation: Skill 
building to engage patients 
6; low; small 
study; good 
background 
information 
Schwappach   
& Wernli,  
2011 
Theory of 
Planned 
Behavior 
Cross-sectional, 
descriptive study; 
survey; follow-up  
to Schwappach et 
al., 2010 
479 adult patients 
receiving 
chemotherapy 
Explore acceptability 
of patients to exhibit 
error preventing 
behaviors 
Response to 
vignettes of errors 
and unsafe acts 
related to 
chemotherapy 
administration 
Cronbach’s 
alpha, mean 
scale scores, 
multiple 
logistic 
regression 
analysis 
-Findings: Patients’ 
willingness to engage varied 
(57-96%, p <0.001) due to 
barriers of health, knowledge, 
and staff time 
-Recommendation:  Staff 
awareness of subjective 
behavior and attitudes of 
patients when engaging in 
error prevention 
6; low; 
hypothetical 
analysis; good 
background 
information; 
supports strategies 
for error 
recognition 
Harris et al., 
2014 
None Cross-sectional, 
descriptive study; 
CPMEP 
questionnaire 
100 caregivers; 
pediatric cancer 
setting 
Explore caregivers’ 
characteristics and 
perception of drug 
administration safety 
-Perceptions of 
safety 
-Knowledge of 
strategies to prevent 
errors 
-Willingness to 
partner with 
professionals in 
error prevention 
Cronbach’s 
alpha; t-tests 
-Findings: Caregivers have 
apprehension about 
responsibility to look for 
errors; hesitant to discuss 
fears; willing to partner to 
prevent errors  
-Recommendation: Enhance 
education and engagement of 
caregivers (r = 0.64) 
6; low; variables 
and reliability 
differ greatly; 
good background 
information; 
supports strategies 
for error 
recognition  
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Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
Trbovich et   
al., 2010 
None Direct observational 
study; shadowing 
17 outpatient 
oncology nurses 
over 3 hours; 4 
months  
Explore nature and 
frequency of 
interruptions during 
chemotherapy 
administration and the 
effects on task 
efficiency 
Nature, frequency, 
timing of 
interruption during 
specific tasks 
Interrater 
reliability; no 
stats; 
percentages 
reported 
-Finding: Nurses interrupted 
22% while administering 
treatments and 29% while 
performing safety-related 
tasks; task completion times 
were greater for those with 
interruptions.  
-Recommendation:    
Decrease interruptions with 
time-out, visual recognition 
of chemotherapy nurse 
6; low; small 
sample; good 
background 
information on 
contribution to 
errors; supports 
strategies for error 
reduction 
Sheridan-  
Leos, 2007 
None Descriptive QI 
study; systems 
analysis 
12 novice oncology 
nurses; community 
hospital; 
24 months  
 
Implement effective 
strategies for error 
prevention by new 
nurses following 
determination of 
potential 
chemotherapy errors 
Error prevention 
following 
standardized 
education and 
system-based safety 
initiative 
No stats; 
Anecdotal  
-Recommendations:  
Proactive approach to      
error prevention;  cultivating 
culture of safety with  proper 
standards, techniques,  
communication, and   
ongoing education and 
competency assessment  
6; low; valuable 
inclusion in 
background 
information; 
utilizes 
recommended 
education process 
 
Prakash et     
al., 2014 
None Descriptive study; 
direct observation; 
3-phase simulation; 
6 months; pre-
intervention, focus 
group,  postinter-
vention; follow-up 
to Trbovich et al., 
2010 
18 oncology nurses 
preintervention;     
19 oncology nurses 
postintervention; 
simulation 
laboratory setting 
Explore association 
between interruptions 
and specific 
pretreatment and 
administration   
errors, effectiveness 
of focus group work 
to reduce 
interruptions and 
errors 
Interruption error 
rates during  medi-
cation verification 
and administration 
tasks, before and 
after focus group 
intervention work to 
decrease 
distractions 
Interrater 
reliability; 
Fisher’s   
exact test  
-Findings: Most significant 
decrease in errors 
postintervention related to 
dose verification (17% 
reduction; p=0.153), volume 
verification (31% reduction; 
p=0.038), pump program 
(34% reduction; p=0.017), 
and IV push administration 
(57% reduction; p=0.001) 
-Recommendations: No-
interruption zones, visual 
timing devices, speaking 
aloud during verification 
activities, reminder signage 
6; moderate; 
hypothetical 
situation with high 
number of “errors” 
presented in 
simulation event; 
good background 
information on 
types of 
distractions and 
errors; supports 
strategies for error 
recognition and 
reduction 
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Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
White et al., 
2010 
None Direct observational 
study; simulated 
laboratory 
13 oncology nurses; 
outpatient care; 
simulation 
laboratory; 
preintervention, new 
checklist 
implemented, 
postintervention  
Compare nurses’ 
ability to detect errors 
with two-person 
verification using old 
and new 
chemotherapy 
administration 
checklists 
Rates of specific 
types of errors 
recognized during 
medication 
administration 
using old and new 
administration 
checklists 
2x4 repeated 
measures; 
ANOVA 
-Findings: Error detection 
decreased with new checklist 
(55% to 38% F [1,9] = 26.64, 
p<0.01)  
-Recommendation: Step-by-
step checklist beneficial to 
error prevention 
6; low; small 
sample; good 
background 
information on  
documentation;  
supports strategies 
for error 
recognition 
Spruill et al., 
2009  
Team 
STEPPS 
Descriptive QI 
study; 
preimplementation 
chart review and 
postimplementation 
chart review  
90 chemotherapy 
treatment chart 
reviews; 6 months 
Describe compliance 
with new bedside 
check for 
chemotherapy patient 
identification 
Consistency of new 
bedside checks 
No stats; 
percentages 
reported 
-Finding: 100% compliance 
with no patient 
misidentification within 6 
months 
-Recommendation: 
Implement additional bedside 
patient identification check 
6; low; only 
compliance 
checked; good 
background 
information on 
documentation;  
supports strategy 
for error 
recognition 
Nerich et       
al., 2010  
None Epidemiologic 
observational 
survey 
14,854 
chemotherapy 
orders; 1 year 
Determine the 
potential incidence 
and clinical impact   
of chemotherapy 
prescribing errors 
discovered by 
pharmacists 
Potential incidence 
and severity of 
chemotherapy 
prescribing errors 
discovered by 
pharmacists  
Multivariate 
analysis; 
stepwise 
logistic 
regression 
model;   
Fisher exact 
test;           
chi-square 
-Findings: 15 errors per   
1000 orders; 3.7% possibly 
fatal if not recognized; 1% 
potentially having clinical 
impact (CI = 95%, p <0.02); 
dosage error most common 
20% of the time by 
occasional CPOE users  
-Recommendation: Enhance 
order analysis and training   
of occasional CPOE users 
6; low; describes 
pharmacists 
reported errors but 
relevant for impact 
of strategies for 
error recognition  
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Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
Bourmaud       
et al., 2014 
None Cross-sectional 
survey 
157 oncologists 
employed by 112 
hospitals;   
outpatient oral 
chemotherapy 
prescriptions 
Gather exhaustive 
information on      
oral chemotherapy 
prescribing    
practices 
-Patient education 
provided 
-Method of    
writing    
prescription 
-Monitoring 
procedures for 
compliance 
-Incidence of 
serious adverse 
events 
No stats; 
percentages 
reported 
-Findings: 56.1% used 
handwritten prescriptions;  
23% with no compliance 
checks; 39% report serious 
adverse events  
-Recommendations: 
Standardize oral 
chemotherapy prescribing 
standards 
6; low; describes 
physician orders 
but relevant for 
impact of 
strategies for error 
reduction  
Watts & 
Parsons,     
2013 
None Prospective QI 
study; 
preimplementation, 
new surveillance 
system, 
postimplementation 
>20,000 
chemotherapy 
orders; pediatric 
oncology setting;     
3 years 
Determine effect      
of new pharmacy 
prospective 
surveillance system 
on error reduction 
Incidence of    
errors per patient 
encounter and      
per prescription; 
number of errors 
intercepted prior    
to reaching patient 
No stats; 
percentages 
reported 
-Findings: Error rates 6/1000 
patient encounters and 
3.9/1000 prescriptions 
reduced to 3/1000 and 
1.8/1000 after surveillance 
implemented; 92% errors 
intercepted before reaching 
patient; no patient harm 
reported 
6; low; describes 
pharmacists 
reported errors but 
relevant for impact 
of strategies for 
error recognition 
Ranchon         
et al., 2011 
None Prospective QI 
study; cost   
analysis 
6,607 chemotherapy 
orders; inpatient 
oncology 
Assess number and 
impact of 
chemotherapy errors 
Frequency,  
severity, and      
cost of errors 
Univariate 
analysis;    
chi-square; 
Kappa stats 
-Findings: 341 errors in 6,607 
orders (5.2%); 91% 
prescriptive errors; 13 
reached patients 
-Recommendations: Need for 
development of systematic 
preventive actions to reduce 
medication errors; continue 
regular review for errors 
 
Ranchon         
et al., 2012 
None Epidemiologic 
observational   
study 
17,150 
chemotherapy 
prescriptions; 
inpatient and 
outpatient    
oncology 
Identify predictors    
of prescription    
errors involving 
antineoplastic    
agents 
-Patient factors 
-Protocol 
complexity 
-Provider writing 
order 
-Modified protocols 
-Type of care 
setting 
Univariate 
analysis; chi-
square; 
multivariate 
analysis 
Findings: 540 errors in 
records (3.15%); highest risk 
factors: BSA >2 (p = 0.005), 
protocols 3 or more drugs (p 
<0.001), protocol needing at 
least one modification (p = 
0.03), prescriptions written  
by resident (p<0.001)  
6; moderate; 
supports known 
contributors to 
errors and 
strategies for error 
reduction 
ASSESSING THE IMPACT OF CHEMOTHERAPY EDUCATION     108 
Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
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Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
DuBeshter       
et al., 2006 
 
 
 
Jia, Zhang, 
Chen, Zhao,    
& Zhang, 
2016 
 
None 
 
 
 
 
 
 
 
None 
 
 
Prospective QI 
study 
 
 
 
 
Literature review 
 
 
2558 drug 
administrations; 
inpatient and 
outpatient   
oncology;  12 
months 
 
20 studies including 
systematic reviews 
 
Determine types       
of errors in 
chemotherapy   
dosing using CPOE 
 
 
Evaluate effects of 
clinical decision 
support on medication 
safety 
 
Errors in drug 
selection, dose 
calculations, 
decimal-point 
errors, exceeding 
warning level set 
 
Rate of errors 
No stats; 
percentages 
reported 
 
 
 
75% found 
significant 
impact on 
medication 
safety 
-Findings: Errors only found 
in dose warning level 
exceeded 
-Recommendation: Higher 
awareness of dose limits    
and upgrading CPOE 
regularly 
-Recommendations: Clinical 
decision support reduces 
medication errors 
 
6; low; supports 
strategies for error 
recognition and 
reduction 
 
 
6; moderate; 
supports known 
contributors to 
errors and 
strategies for error 
reduction 
Harris & 
Northfelt,   
2005 
None Case study for      
QI initiative; 
literature review 
1 patient; 
chemotherapy error 
occurrence causing 
patient harm 
Describe potential 
models for 
chemotherapy      
error reporting     
based on case study 
None No stats -Findings from literature 
review: Postulates 
comprehensive reporting   
will lead to more robust 
understanding and reduced 
error incidence 
-Recommendations: multiple 
systems, unit, individual  
7; moderate; good 
composite 
literature review; 
information on 
documentation;  
strategies for error 
recognition,  
reporting, and 
reduction 
Schulmeister, 
2006 
None Literature review Not stated Review principles    
of safe chemotherapy 
administration and 
key actions to prevent 
errors 
None No stats -Recommendations: 
Recognize mistakes occur; 
create culture of safety;  
clear, unambiguous 
chemotherapy orders; 
ongoing staff education     
and reliable resources; 
reliable patient identification 
processes; establish error 
reporting process 
7; low; number of 
reviews not 
provided; use as 
background 
information on 
specific error 
prevention 
processes  
 
Schulmeister, 
2008 
 
None 
 
Literature review 
 
Not stated 
 
 
Explore process of 
patient identification 
 
None 
 
No stats 
 
 
-Recommendation: 
Consistently verify patient 
 
7; low; number of 
reviews not 
provided;  
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Citation Theoretical 
Framework 
Design and/or 
Methods 
Sample and 
Setting 
Aim and Major 
Variables 
Studied 
Outcomes 
Measured or 
Discussed 
Data 
Analysis 
Findings and 
Recommendations 
Level and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Quality of 
Evidence 
and factors 
contributing to patient 
misidentification prior 
to oncology care 
identity using two unique 
patient identifiers 
background 
information on 
documentation 
and error 
recognition 
Note. Publications are listed from highest level of evidence to lowest level of evidence. Levels of evidence are based on the rating system for the hierarchy of 
evidence for intervention/treatment questions (Melnyk & Fineout-Overholt, 2015, p. 11). 
FMEA – Failure Mode Effects Analysis quality improvement model 
SBAR – Situation Background Assessment Recommendation quality improvement model  
PDCA – Plan-Do-Check-Act quality improvement model 
PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analysis model 
AIRE – Appraisal of Indicators through Research and Evaluation instrument  
CPMEP – Caregiver Partnership in Medication Error Prevention questionnaire 
ANOVA – Analysis of Variance 
RISQ – Reporting to Improve Safety and Quality error database 
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Table 4 
Synthesis of Best Practice Recommendations: Critical Behaviors and Unit and System-based Structures and Processes that Support Critical 
Behavior and Drive Compliance to Guidelines/Standards for Chemotherapy Error Prevention, Recognition, and Reporting 
 
Supporting System-based Structures Supporting Unit-based Processes Critical Individual Nurse Behaviors 
-Adopt guidelines and standards (ASHP, 2015; IHI, 2012; 
JC, 2016; Neuss et al., 2013; Neuss et al., 2016; Polovich et 
al., 2014) 
-Recognize mistakes occur and their potential impact 
(AHRQ, 2016; Brady et al., 2009; Harris & Northfelt, 2005; 
JC, 2016) 
-Prioritize the error issue, allow adequate staff time to 
implement, evaluate and maintain change (Brady et al., 
2009; Harris & Northfelt, 2005) 
-Proactively cultivate a culture of safety (AHRQ, 2016; Fyhr 
et al., 2015; Farag et al., 2017; Hung et al., 2016; JC, 2016; 
Richardson & Storr, 2010; Schulmeister, 2006; Sheridan-
Leos, 2007; Trbovich et al., 2010) 
-Implement preprinted order sets or other clear unambiguous 
ordering process (Harris & Northfelt, 2005; JC, 2005; JC, 
2016; Robinson, et al., 2006; Schulmeister, 2006)  
-Implement CPOE (Cheng et al., 2012; Harris & Northfelt, 
2005; ISMP, 2016; Kullberg, et al., 2013) 
-Train all users for chemotherapy entry into CPOE (Nerich, 
et al., 2010).  
-Standardize chemotherapy prescription, education, and 
monitoring (Bourmaud et al., 2014; ISMP, 2016; Walsh et 
al., 2013; Weingart et al., 2010) 
-Implement CPOE upgrades (Gandhi et al., 2005): embedded 
checklists (Dobish et al., 2016); policies for vulnerabilities 
(Harris & Northfelt, 2005); chemotherapy alerts, clinical 
decision support, vocabulary; order templates, barcodes 
(Baldwin & DuBeshter et al., 2006; ISMP, 2016; Jia et al., 
2016; Rodriguez, 2016; Ranchon et al., 2011; Watts & 
Parsons, 2013) 
-Ensure environmental improvements to limit distractions 
(Farag et al., 2017; Harris & Northfelt, 2005) 
-Establish guidelines for recognition and immediate action to 
chemotherapy overdose (Fyhr et al., 2015; Nelson et al., 
2014) 
-Establish non-punitive reporting system that is 
comprehensive, quickly identifies the need for proactive or 
reactive actions (AHRQ, 2016; Brady et al., 2009; Fyhr et 
-Implement guidelines and standards (ASHP, 2015; IHI, 
2012; ISMP, 2016; JC, 2016; Neuss et al., 2013; Neuss et 
al., 2016; Polovich et al., 2014) 
-Provide comprehensive chemotherapy education, annual 
competency testing, and include simulation of error 
events (Brady et al., 2009; Daupin et al, 2016; Harris & 
Northfelt, 2005; Neuss et al., 2013; Neuss et al., 2016; 
Polovich et al., 2014; Schulmeister, 2006) 
-Combine education with formal and informal 
evaluations (Daupin et al., 2016; Sheridan-Leos, 2007) 
-Assure safe preassessment practices with step-by-step 
checklist and indicators (White et al., 2010)  
-Include independent and two-person dose verification, 
dose limits, patient education (Harris & Northfelt, 2005)  
-Consider employment of verification nurse (Baldwin & 
Rodriguez, 2016)  
-Consider interprofessional order surveillance team 
(Markert et al., 2009) 
-Integrate no-interruption zones, visual timing devices, 
reminder signage (Prakash et al., 2014) 
-Assure precautions with investigational agents that have 
adequate references for staff (Gandhi, et al., 2005) 
-Improve transition of care communication (Walsh et al., 
2013; Harris & Northfelt, 2005) 
-Assure time for routine review of error occurrences by 
staff (Harris & Northfelt, 2005) 
-Implement oncology practice guidelines and standards 
(ASHP, 2015; Fyhr et al., 2015; IHI, 2012; Neuss et al., 
2013; Neuss et al., 2016; Polovich et al., 2014) 
-Assure error reporting system is available and feasible 
for use by nurses (Brady et al., 2009; Fyhr et al., 2015; 
Harris & Northfelt, 2005; Nelson et al., 2014) 
-Motivate and encourage to overcome fear of 
punishment, time constraints, and a lack of perceived 
benefit to reporting errors (AHRQ, 2016; Fyhr et al., 
2015; Harris & Northfelt, 2005; Hung et al., 2016; 
McNab et al., 2016)  
-Demonstrate compliance with practice guidelines and 
standards (ASHP, 2015; IHI, 2012; JC, 2016; Neuss et al., 
2013; Polovich et al., 2014) 
-Enhance confidence and personal accountability 
(Schwappach & Gehring, 2015) 
-Assure compliance with CPG and SoC processes for safe 
chemotherapy administration, including independent 
verification followed by two-person verification (Brady et 
al., 2009; Harris & Northfelt, 2005; Looper et al.. 2015; 
Neuss et al., 2013; Neuss et al., 2016; Smeulers et al., 
2015) 
-Maintain vigilance in risk assessment (Endsley, 1995) 
-Speak aloud when performing verification activities 
(Prakash et al., 2014) 
-Initiate bedside patient identification (Spruill et al., 2009) 
-Consistently verify patient identity using two unique 
patient identifiers (Looper et al. 2015; Schulmeister, 2006; 
Schulmeister, 2008) 
-Eliminate interruptions: time outs, quiet verification areas 
(Harris & Northfelt, 2005; Trbovich et al., 2010) 
-Consider patients partners in safety (Schulmeister, 2008). 
-Improve consent process to include full treatment 
information and planning (Nelson et al., 2014) 
-Educate and engage patients in error prevention behaviors 
(Kullberg et al., 2013; Schwappach et al., 2010) 
-Engage patients/caregivers in verification, monitoring, 
teach-back, reporting any symptoms, and document 
confirmation of engagement (Etchegaray et al., 2016; 
Harris et al., 2014; Kullberg et al., 2013; Schwappach, 
Hochreutener, & Wernli, 2010; Schwappach & Wernli, 
2010; Shojania et al., 2001)  
-Be aware of barriers to engagement that are interpersonal 
and individual (Schwappach & Wernli, 2011) 
- Demonstrate compliance with oncology practice 
guidelines and standards (AHRQ, 2016; ASHP, 2015; IHI, 
2012; Neuss et al., 2013; Neuss et al., 2016; Polovich et 
al., 2014) 
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Supporting System-based Structures Supporting Unit-based Processes Critical Individual Nurse Behaviors 
al., 2015; Harris & Northfelt, 2005; Nelson et al., 2014; 
Schulmeister, 2006) 
-Investigate error reporting systems to meet organizational 
needs (Brady et al., 2009; Harris & Northfelt, 2005; Nelson 
et al., 2014) 
-Prioritize errors; allow adequate staff time to implement, 
evaluate and maintain (Harris & Northfelt, 2005) 
-Remember to learn from safety errors (AHRQ, 2016; 
Macrae, 2016) 
-Offer open forums and individual sessions to build 
confidence in reporting and communication for advocacy 
(Schwappach & Gehring, 2015) 
-Provide team building and trust building work (Farag et 
al., 2017; Schwappach & Gehring, 2015) 
-Consistently utilize error reporting system (Brady et al., 
2009; Harris & Northfelt, 2005; Nelson et al., 2014) 
-Develop accountability (McNab et al., 2016; Schwappach 
& Gehring, 2015) 
 
 
Table 5 
 
Theoretical Model Components Related to Overall Survey Intent 
Overall Survey Themes New World Kirkpatrick Model (NWKM): 
Level of Evaluation 
Knowledge-to-Action (KTA): 
Action Cycle Phase 
 
Are changes in critical individual practice 
behaviors and supporting organizational 
processes perceived as needed by nurse 
participants following completion of the 
ONS/ONCC course? 
 
Level Three: assesses perception of need for 
changes in critical behaviors and required drivers. 
 
 
 
 
1. Phase Two: assesses acceptance of knowledge to 
specific practice environments. 
2. Phase Five: monitors knowledge use. 
 
 
Have changes in critical individual practice 
behaviors and supporting organizational 
processes been initiated by nurse 
participants as a result of the ONS/ONCC 
educational program content? 
 
Level Three: assesses for initiated changes in 
critical behaviors and required drivers. 
 
 
1. Phase Two: assesses adaptation of knowledge by 
stakeholders within specific practice environments.  
2. Phase Five: monitors knowledge use. 
    
 
What barriers may prevent nurse 
participants from initiating changes in 
critical individual practice behavior and 
supporting organizational processes?  
 
 
Level Three: assesses issues related to 
accountability for initiating change in on-the-job 
learning. 
 
1. Phase Three: assesses barriers to knowledge use related 
to stakeholders within specific practice environments.  
2. Phase Five: monitors knowledge use. 
   
(Graham et al., 2006; Kirkpatrick Partners, 2016) 
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Table 6 
Identification of Evidence-based Individual Chemotherapy Error Prevention Behaviors and Organizational Processes that are Supportive of and 
Compliant with Guidelines and Standards and Included in ONS/ONCC Chemotherapy and Biotherapy Certificate Course and based on Domain of 
Organizational Context as described in the Alberta Context Tool (ACT) 
Care Phase Individual Error 
Prevention Behavior 
Organizational Error 
Prevention Process 
Guideline or Standard 
Reference 
ACT Organizational Context Domain 
Pretreatment Confirm planned 
treatment education and 
consent for treatment with 
the patient. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, formal and 
informal interactions, structural and 
electronic resources 
Pretreatment Review current list of 
other medications for 
potential drug-drug 
interactions. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, structural and 
electronic resources 
Pretreatment Verify and document 
actual patient height and 
weight. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, structural and 
electronic resources 
Pretreatment Ensure and document two 
chemotherapy competent 
staff are engaged in 
verification process. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, formal interactions,  
structural and human resources 
Pretreatment Use of verification 
process minimally 
includes verification of 
each drug’s name, dose, 
volume, administration 
route, administration rate, 
expiration date, and 
physical appearance. 
 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, formal interactions,  
human resources, structural and 
electronic resources 
Pretreatment Use and document only 
generic drug names.  
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, structural and 
electronic resources 
Pretreatment Verify and document any 
specific dose and volume 
determination or change 
based on protocol or 
notation in orders. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, informal 
interactions, human resources, 
structural and electronic resources 
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Care Phase Individual Error 
Prevention Behavior 
Organizational Error 
Prevention Process 
Guideline or Standard 
Reference 
ACT Organizational Context Domain 
Pretreatment Verify and document 
cumulative dose received 
and dose limits based on 
body surface area and 
patient history for drugs 
requiring tracking. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, informal 
interactions, structural and electronic 
resources 
Pretreatment Verify and document 
correct use of hazardous 
drug label. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, human resources, 
structural and electronic resources 
 
Pretreatment Verify and document 
administration sequence 
of drugs in regimen. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, structural and 
electronic resources 
Pretreatment Two individuals verify 
and document patient 
identification at bedside. 
Policy and procedure to 
support task within 
verification process 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, formal interactions,  
human resources, structural and 
electronic resources 
Administration Utilize infusion pump to 
eliminate gravity 
infusions. 
 
Policy and procedure to 
support task within 
administration process 
Polovich et al., 2014 Leadership, culture, structural and 
electronic resources 
Administration Use infusion set-up with 
immediate access to 
primary flush line. 
Policy and procedure to 
support task within 
administration process 
Polovich et al., 2014 Leadership, culture, structural and 
electronic resources 
Administration Assess and document site 
assessment. 
Policy and procedure to 
support task within 
administration process. 
Polovich et al., 2014 Leadership, culture, structural and 
electronic resources 
Administration Assess and document 
treatment tolerance 
including any immediate 
effects. 
Policy and procedure to 
support task within 
administration process. 
Neuss et al., 2013; 
Polovich et al., 2014 
Leadership, culture, informal 
interactions, structural and electronic 
resources 
(Neuss et al., 2013; Polovich et al., 2014) 
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Appendix B: Figures and Diagrams 
Figures B1, B2, B3, B4, B5 
Figure 1 
Root Cause Analysis of Chemotherapy Errors Utilizing Ishikawa (Fishbone) Diagram (Warren, 2014) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemotherapy 
Error  
Individual Factors: Nurse 
 Patient, dose, and order verification 
processes not followed  
 Regimen order or procedure not followed 
 Processes and orders followed but human 
error occurs 
 Fatigue, hurrying, carelessness, lack of 
attention, no “time out” 
 Deficit in knowledge, skill, or technology  
 Reluctance to question orders 
 Fear of retribution for error reports 
 High workload, stress, fatigue levels 
 
Unit-based Factors: Nurse Training  
 Knowledge deficit regarding 
chemotherapy error importance 
 Unfamiliarity with cancer type or  
treatment regimen 
 Inadequate chemotherapy-competent 
staff  
 Inadequate chemotherapy-specific 
resources 
 Inadequate standards of care 
resources and adherence 
 Unsure of error reporting process 
 
Unit-based Factors: Communication  
 Lack of collaboration during patient, 
dose, and order verification processes 
 Intra/interprofessional  
miscommunication regarding patient, 
dose, or regimen 
 Lack of proper supervision or clinical 
resources  
 Lack of access to previous orders or 
standards of care for comparison 
 Poor transition of care communication 
 
  
 
Unit-based Factors: Tasks 
 High alert medication concerns  
 Wide dosage variations with dose-
limiting toxicities  
 Complex regimens and care 
 Dose modifications  
 Look-alike, sound-alike drugs 
 Need for alerts or notifications 
 Lack of verification procedures 
 Lack of proper patient identification 
 “Time out” before administration  
 High staff workload and stress 
 
Individual Factors: Patient 
 Inadequate education process 
 Inadequate consent process   
 Limited patient engagement in 
verification process  
 Inability of patient to engage due to 
psychosocial or cognitive distress 
 Lack of recognition of coexisting 
conditions or medication interactions 
 Visitors or other distractions 
 
System-based Factors: Resources  
 CPOE not customizable to oncology 
or needs upgrade 
 Lack of access to previous orders 
 System inability to send alerts 
 Lack of consistent error reporting 
process  
 Lack of compliance with standards  
 Inadequate decision tools  
 Improper ordering/labeling process 
System-based Factors: Leadership 
 Uncommitted to culture of safety 
 Punitive reporting process 
 Disengaged leaders 
 Limited experience with 
chemotherapy error events 
 Lack of qualified supervision 
 Need for evidence-based policies/ 
procedures  
 Need for compulsory adherence to 
standards/guidelines 
 
 
Unit-based Factors: Environment 
 
 Distraction and interruptions 
 Excessive noise 
 Need for safety-based floor design 
 Potential for environmental 
contamination with hazardous agents 
(ASCO, 2016; AHRQ, 2016; ASHP, 2015; CCO, 2012; CCO, 2014; Farag et al., 2016; Fyhr et al., 2015; Hung et al., 2016; IHI, 2012; IOM, 1999a; IOM, 2013; ISMP, 
2016; Keers et al., 2013; Kloth, 2010; Lennes et al., 2016; Nelson et al., 2014; Neuss et al., 2013; Neuss et al., 2016; Polovich, 2015; Polovich, et al., 2014; Schulmeister, 
2006; Schulmeister, 2008; Schwappach & Wernli, 2011; Walsh et al., 2009; Warren, 2014; Weber & Sidorov, 2014) 
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Figure 2 
The New World Kirkpatrick Model of Evaluation (NWKM) (Kirkpatrick Partners, 2016)1 
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Figure 3 
The Knowledge-to-Action (KTA) Framework with Action Cycle (Graham et al., 2006)2
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Figure 4 
The Evidence-based Advancing Research and Clinical Practice through Close Collaboration (ARCC©) 
Model (Melnyk, 2012; Melnyk & Fineout-Overholt, 2015; Melnyk, Fineout-Overholt, Gallagher-Ford, & 
Stillwell, 2011; Melnyk et al., 2017) 3 
The ARCC Model
Potential Strengths
Philosophy of EBP (paradigm 
is system-wide
Presence of EBP Mentors & 
Champions
Administrative Support
 Nurses’ Beliefs about 
the Value of EPB & 
Ability to Implement 
the EBP Process*
 EBP 
Implementation*+
Decreased 
Hospital 
Costs
Potential 
Barriers
Lack of EBP 
Mentors & 
Champions
Inadequate EBP 
Knowledge & 
Skills
Lack of EBP 
Valuing
Interactive EBP 
Skills Building 
Workshops
EBP Rounds & 
Journal Clubs
Implementation 
of ARCC 
Strategies
*Scale Developed
+ Based on the 
EBP paradigm & 
using the EBP 
process
© Melnyk & Fineout-Overholt
2005
Assessment of 
Organizational 
Culture & 
Readiness for 
EBP*
Identification of 
Strengths & 
Major Barriers 
to EBP 
Implementation
Development 
& Use of EBP 
Mentors
Improved 
Patient 
Outcomes
 Nurse 
Satisfaction
 Cohesion
 Intent to 
Leave
 Turnover
 
 
Innovative Clinical 
Decision-making 
Quality
Patient 
Outcomes
Research Evidence & 
Evidence-based 
Theories 
Clinical Expertise (e.g., evidence from 
practice, patient assessment & use as well as 
use  of healthcare resources)
Patient 
Preferences 
& Values 
Context of Caring*
© Melnyk & Fineout-Overholt, 2003
EBP Organizational Culture
•The Context of Caring allows for individualization of the patient-
provider relationship
The Conceptual Framework to Support the EBP Paradigm
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Figure 5 
The Alberta Context Tool (ACT) Applied to the Facilitation of Chemotherapy Error Prevention. Image 
created based on Domains of Care within the ACT Acute Care Nursing Version and used to develop list 
of potential barriers to practice change (Squires et al., 2014). 
 
Chemotherapy 
Error 
Prevention
Leadership Domain
• Actively listens
• Acknowledges concerns
• Responds to concerns
Human Resources 
Domain
• Promote information 
sharing
• Allow comfortable 
sharing of concerns
Electronic Resources 
Domain
• Assure availability and 
dependability of tools and 
equipment
Structural Resources 
Domain
• Ensure appropriate 
staffing, time, physical 
environment
• Promote guidelines, 
policies, and procedures
Formal Interactions 
Domain
• Involve team meetings
• Include patient rounds 
and conferences
• Continue staff education
Informal Interactions 
Domain
• Involve patient related 
discussions
• Include nurses, 
physicians, quality 
improvement specialist, 
education staff
Culture Domain
• Prioritizes safety
• Utilizes best practices
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Appendix C: Project Survey 
 
Chemotherapy Error Prevention Survey Invitation and Content 
 
 
Chemotherapy Error Prevention Survey Invitation 
 
 Did you know most chemotherapy errors are recognized during critical pretreatment and 
treatment administration nursing tasks? As the final checkpoint prior to treatment administration, the 
nurse’s role in recognizing and reporting chemotherapy errors is vitally important to prevent patient harm. 
The foremost proactive strategy to enhance the nurse’s role in preventing chemotherapy errors is 
comprehensive education and subsequent development of chemotherapy-competent nurses. 
 
 Because you have successfully completed the comprehensive ONS/ONCC Chemotherapy and 
Biotherapy Certificate course, ONS desires to know how you have improved practice to address 
chemotherapy error prevention. ONS is inviting you to participate in a survey to assess how you have 
used knowledge attained from the course to initiate individual and organizational change. The survey 
reflects course and e-book content specific to chemotherapy error prevention.  
 
 The survey is estimated to take less than 10 minutes to complete, and all survey responses will be 
anonymous and your personal information will not be identified. Survey outcomes will be included in a 
future ONS publication. The data collected will be used to enhance current and future chemotherapy 
educational offerings, and to determine the need for tools to overcome barriers to practice change.  
 
To participate in the survey, please go to the following link: [ ] 
If you have questions about this survey, please email twyant@ons.org.  
 
Chemotherapy Error Prevention Survey Content 
 
Thank you for participating in the Chemotherapy Error Prevention survey! The survey is estimated to take 
less than 10 minutes to complete. All survey responses are anonymous and your personal information will 
not be identifiable.  
 
Definition: For this survey, “chemotherapy” is considered to be any antineoplastic agent given by the 
intravenous route and used to treat cancer.  
 
About Your Practice: Please select the appropriate answers related to your level of practice, nursing 
experience, and care setting. 
 
1. What is your age? 
  20-29 
  30-39 
  40-49 
  50-59 
  60-69 
  > 70 
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2. What is the highest nursing degree you have attained? 
 Associate degree 
 Diploma 
 Baccalaureate degree 
 Master’s degree  
 Doctoral degree 
 
3. Which professional oncology certification credentials have you attained? (Select all that apply)  
 OCN® 
 AOCN® 
 AOCNS® 
 AOCNP® 
 CBCN® 
 BMTCN® 
 CPHON® 
 No oncology certification 
 
4. How many years have you practiced nursing?  
 <1 
 1-3 
 4-9 
 10-14 
 15-19 
 20-24 
 25+ 
 
5. How many years have you practiced oncology nursing?   
 <1 
 1-3 
 4-9 
 10-14 
 15-19 
 20-24 
 25+ 
 No oncology experience 
 
6. How many years of experience do you have in chemotherapy administration? 
 <1 
 1-3 
 4-9 
 10-14 
 15-19 
 20-24 
 25+ 
 No chemotherapy experience 
 
7. What is the care setting in which the majority of your chemotherapy nursing hours (administration or 
post-treatment care) are spent? 
 Inpatient oncology  
 Inpatient non-oncology  
 Intensive care   
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 Ambulatory oncology  
 Other ambulatory or infusion center 
 Bone marrow or stem cell transplant unit 
 Hospice/palliative care 
 Home care 
 Long-term care 
 Other non-oncology care 
 Do not provide chemotherapy care 
 
8. What is the patient population to which your chemotherapy nursing care is provided? (Select all that 
apply) 
 Adult 
 Pediatric 
 Diagnosis- or site-specific 
 Do not provide chemotherapy care 
 
9. In which U.S. state do you practice?  
 Drop-down list of U.S. states with international option 
 
10. In what month and year did you complete the ONS/ONCC Chemotherapy and Biotherapy Certificate 
course? 
 October 2015 
 November 2015 
 December 2015 
 January 2016 
 February 2016 
 March 2016 
  
 
Pretreatment Error Prevention: Select one response that best reflects your perception of changes you 
have made during pretreatment care since completing the ONS/ONCC Chemotherapy and Biotherapy 
Certificate course.  
1. Confirm planned treatment education and patient consent for treatment are documented. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
2. Review allergies and current list of all medications for potential interactions. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
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3. Verify and document actual patient height and weight.  
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
4. Ensure and document order completeness by verifying each drug’s name, dose, volume, 
administration route, administration rate, expiration date, and physical appearance. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
5. Ensure and document that two chemotherapy competent staff are engaged in chemotherapy order 
verification process. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
6. Use and document only generic (not brand or trade) drug names. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
7. Verify and document dose variations and rationale for each variation. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
8. Verify and document any drug-specific cumulative dose and dose limits. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
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9. Verify and document administration sequence of drugs in regimen. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
10. Verify and document correct hazardous drug labeling. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
11. Ensure and document that two individuals verify patient identification. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
Treatment Administration Error Prevention: Select one response that best reflects your perception of 
changes you have made when administering treatment since completing the ONS/ONCC Chemotherapy 
and Biotherapy Certificate course. 
1. Utilize infusion pump to eliminate gravity infusions. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
2. Use infusion set-up with immediate access to primary flush line and emergency equipment.   
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
3. Assess and document administration site and its appearance. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
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4. Assess and document treatment tolerance including any immediate effects. 
 I consistently performed this behavior prior to course completion and no change was needed. 
 I sometimes or mostly performed this behavior prior to course completion and am now more aware of 
the need to perform it. 
 I did not perform this behavior prior to course completion and have since started performing the 
behavior. 
 I did not perform this behavior prior to course completion and still do not perform it. 
 
Organizational Error Prevention Policies and Procedures: Select one response that best reflects your 
perception of changes you have been involved in within your organization since completing the 
ONS/ONCC Chemotherapy and Biotherapy Certificate course.  
1. Policies and procedures that support and detail the steps and components needed in the pretreatment 
nursing verification process. 
 I know effective policies and procedures were already in place prior to course completion and no 
change was needed. 
 I know these policies and procedures were already in place, but I started discussions or approached 
peers and/or nurse leaders about the need to review or revise specific policies and procedures. 
 I know these policies and procedures were already in place, but do not know if changes are needed.  
 I know these policies and procedures were not previously in place and are still not in place. 
 I am unsure if these policies and procedures are in place. 
 
2. Policies and procedures that support and detail the steps and components needed in the treatment 
administration process. 
 I know effective policies and procedures were already in place prior to course completion and no 
change was needed. 
 I know policies and procedures were already in place, but I started discussions or approached peers 
and/or nurse leaders about the need to review or revise specific policies and procedures. 
 I know these policies and procedures were already in place, but do not know if changes are needed.  
 I know these policies and procedures were not previously in place and are still not in place. 
 I am unsure if these policies and procedures are in place. 
 
3. Policies and procedures that support and detail nursing pretreatment and treatment administration 
documentation requirements. 
 I know effective policies and procedures were already in place prior to course completion and no 
change was needed. 
 I know policies and procedures were already in place, but I started discussions or approached peers 
and/or nurse leaders about the need to review or revise specific policies and procedures. 
 I know these policies and procedures were already in place, but do not know if changes are needed.  
 I know these policies and procedures were not previously in place and are still not in place. 
 I am unsure if these policies and procedures are in place. 
 
Barriers to Individual Practice Change: Please select any and all statements that reflect your perception 
of challenges you may encounter or have encountered when initiating error prevention change in your 
own personal practice. 
 I am unsure or unaware of the chemotherapy error prevention strategies for nurses that are 
recommended in the guidelines and standards. 
 I am unsure or unaware of nursing policies and procedures in my practice setting that may help me to 
prevent chemotherapy errors. 
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 I do not feel the chemotherapy educational program provided enough information about how I can 
prevent chemotherapy errors. 
 I do not have enough time to make changes in my pretreatment and treatment administration tasks. 
 I am reluctant to change my own practice because it will be different from the practice of other 
nurses. 
 I have mentioned changes to other nurses but they have questioned the changes I want to make. 
 I need to find ways to more effectively engage patients in chemotherapy error prevention. 
 I believe the physician and pharmacist are responsible to verify orders to prevent chemotherapy 
errors. 
 I believe that using computerized order systems and electronic health records eliminates the risk for 
chemotherapy errors. 
 I have not encountered any barriers to initiating change in my own practice or did not need to initiate 
change in my own practice. 
 
Barriers to Organizational Policy and Procedure Change: Please select any and all barriers that reflect 
your perception of challenges you may encounter or have encountered in initiating change to error 
prevention policies and procedures within your practice setting. Examples of this type of change include 
the development or revision of policies, procedures, documentation forms, and quality improvement 
monitoring. 
 
 Leaders in my organization lack knowledge regarding error prevention strategies. 
 Leaders in my organization lack understanding regarding the need for change. 
 Leaders in my organization are not receptive to ideas for change. 
 My organization does not prioritize chemotherapy error prevention strategies. 
 Policies and procedures in my organization do not or may not include provide best practices for 
chemotherapy error prevention. 
 Effective interprofessional communication is lacking in my organization. 
 Ongoing education and monitoring for the prevention of errors is lacking in my organization. 
 Inadequate staffing and time constraints affect compliance with policies and procedures in my 
organization. 
 Evidence and resources to validate the need for change in my organization are lacking. 
 Electronic ordering and documentation systems are not easily changed or are not integrated in my 
organization. 
 The culture in my organization makes me reluctant to offer suggestions. 
 Recommending additional error prevention strategies in policies and procedures may lead to a higher 
risk for punitive action if those tasks are not performed. 
 I have not encountered any barriers to initiating change in policies and procedures or did not need to 
initiate change to policies and procedures. 
 
Additional Information: When providing chemotherapy care, please describe what you do differently 
that helps to identify or prevent chemotherapy errors as a result of the knowledge you have attained and 
guidelines that were provided in the ONS/ONCC Chemotherapy Certificate course and accompanying e-
book? 
_____________________________________________________________________________________
_____________________________________________________________________________________ 
 
Thank you for participating in the Chemotherapy Error Prevention survey! The data collected will be used 
to enhance current and future chemotherapy educational offerings, and to determine the need for tools to 
overcome barriers to practice change. If you have questions about this survey, please email 
twyant@ons.org.  
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Appendix D: Findings 
Tables 1, 2, 3, 4, 5, 6, 7, 8 
Table 1   
Participant Characteristics (N = 334) 
 
Characteristics  Frequency (%) 
Age 
   20-29 years 
   30-39 years 
   40-49 years 
   50-59 years 
   60-69 years  
 
60 (18.0) 
91 (27.3) 
79 (23.7) 
80 (24.0) 
24   (7.0) 
Nursing Degree 
   Associate  
   Diploma 
   Baccalaureate  
   Master’s  
   Doctoral  
 
95 (28.4) 
         19   (5.7) 
185 (55.4) 
          32   (9.6) 
            3   (0.9) 
Oncology Certification* 
   Oncology Certified Nurse (OCN®) 
   Advanced Oncology Certified Nurse (AOCN®) 
   Advanced Oncology Clinical Nurse Specialist (AOCNS®) 
   Advanced Oncology Certified Nurse Practitioner (AOCNP®) 
   Certified Breast Care Nurse (CBCN®) 
   Bone Marrow Transplant Certified Nurse (BMTCN®) 
   Certified Pediatric Hematology Oncology Nurse (CPHON®) 
   No oncology certification 
 
143 (42.8) 
8  (2.4) 
5  (1.5) 
2  (0.6) 
14  (4.2) 
7  (2.1) 
1  (0.3) 
158 (47.3) 
Years of Nursing Practice 
   <1 
   1-3 
   4-9 
   10-14 
   15-19 
   20-24 
   ≥25 
 
6   (1.8)   
56 (16.6) 
81 (24.5) 
51 (15.0) 
29   (8.8) 
28   (8.5) 
83 (24.8) 
Years of Oncology Nursing Practice 
   0 
   <1 
   1-3 
   4-9 
   10-14 
   15-19 
   20-24 
   ≥25 
 
1   (0.3) 
23   (6.9) 
95 (28.5) 
84 (25.2) 
41 (12.3) 
39 (11.4) 
19   (5.7) 
32   (9.7) 
Years of Chemotherapy Nursing Care 
   <1 
   1-3 
   4-9 
   10-14 
   15-19 
   20-24 
   ≥25 
 
52 (15.3) 
82 (24.6) 
77 (23.1) 
40 (12.0) 
38 (11.5) 
20   (6.0) 
25   (7.5) 
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Table 1 (continued) 
Characteristics  Frequency (%) 
Primary Care Setting 
   Inpatient oncology 
   Inpatient non-oncology 
   Intensive care 
   Outpatient oncology 
   Infusion center 
   Bone marrow transplant (BMT) 
   Hospice/palliative care 
   Other 
   Do not provide chemotherapy care 
 
112 (33.6) 
12   (3.6) 
3   (0.9) 
114 (34.2) 
67 (20.1) 
22   (6.4) 
2   (0.6) 
1   (0.3) 
1   (0.3) 
Month and Year of Course Completion 
   October 2015 
   November 2015 
   December 2015 
   January 2016 
   February 2016 
   March 2016 
 
51 (15.2) 
53 (15.8) 
70 (21.2) 
48 (14.5) 
46 (13.6) 
66 (19.7) 
*Participants selected any and all oncology certifications held, with five selecting more than one. 
Note: Characteristics correspond to “About Your Practice” survey questions (See Appendix C).  
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Table 2 
Perceived Impact on Practice:  
Individual Pretreatment Error Prevention Behavior Variables (N = 334) 
Pretreatment Error 
Prevention Behaviors 
Consistently 
performed; no 
change needed1 
Sometimes or 
mostly performed; 
more aware of 
need to perform2* 
Did not perform; 
have started 
performing3* 
Did not perform; 
still do not 
perform4 
Frequency (%) Frequency (%) Frequency (%) Frequency (%) 
1. Confirm treatment 
education and patient consent 
are documented. 
 
243 (73.0%) 
 
22   (6.6%)* 
 
4 (1.2%)* 
 
65 (19.2%) 
2. Review allergies and 
current medication list for 
potential interactions. 
 
232 (69.4%) 
 
16   (4.8%)* 
 
7 (2.1%)* 
 
79 (23.7%) 
3. Verify and document 
actual patient height and 
weight.  
 
257 (77.4%) 
 
26   (7.9%)* 
 
5 (1.5%)* 
 
46 (13.2%) 
4. Document order 
completeness by verifying 
each drug’s name, dose, 
volume, administration route 
and rate, expiration date, and 
physical appearance. 
 
 
272 (81.9%) 
 
 
16   (4.8%)* 
 
 
3 (0.9%)* 
 
 
43 (12.4%) 
5. Ensure and document two 
chemotherapy competent 
staff engaged in order 
verification. 
 
283 (85.0%) 
 
20   (6.0%)* 
 
5 (1.5%)* 
 
26   (7.5%) 
6. Use and document only 
generic (not brand or trade) 
drug names. 
 
109 (32.7%) 
 
54 (16.3%)* 
 
23 (6.9%)* 
 
148 (44.1%) 
7. Verify and document dose 
variations and rationale for 
variations. 
 
186 (56.0%) 
 
39 (11.8%)* 
 
13 (3.9%)* 
 
96 (28.3%) 
8. Verify and document drug-
specific cumulative dose and 
dose limits. 
 
144 (43.0%) 
 
63 (19.1%)* 
 
27 (8.2%)* 
 
100 (29.7%) 
9. Verify and document 
administration sequence of 
drugs in regimen. 
 
238 (71.5%) 
 
32   (9.6%)* 
 
2 (0.6%)* 
 
62 (18.3%) 
10. Verify and document 
correct hazardous drug 
labeling. 
 
240 (72.0%) 
 
20   (6.0%)* 
 
12 (3.6%)* 
 
62 (18.4%) 
11. Ensure and document two 
individuals verify patient 
identification. 
 
291 (87.3%) 
 
9   (2.7%)* 
 
10 (3.0%)* 
 
24   (7.0%) 
Note: Numbered variables correspond to “Pretreatment Error Prevention” survey (See Appendix C). 
*Impact on practice is considered to have occurred if respondents selected either response option 2 or 3.  
Footnotes: Full survey response options:  
1 I consistently performed this behavior prior to course completion and no change was needed. 
2 I sometimes or mostly performed this behavior prior to course completion and am now more aware of the need to perform it. 
3 I did not perform this behavior prior to course completion and have since started performing the behavior. 
4 I did not perform this behavior prior to course completion and still do not perform it. 
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Table 3 
Perceived Impact on Practice:  
Individual Treatment Administration Error Prevention Behavior Variables (N = 334) 
Treatment Administration Error 
Prevention Behavior  
Consistently 
performed; no 
change needed1 
Sometimes or 
mostly 
performed; more 
aware of need to 
perform2* 
Did not 
perform; have 
started 
performing3* 
Did not 
perform; still do 
not perform4 
Frequency (%) Frequency (%) Frequency (%) Frequency (%) 
1. Utilize infusion pump to eliminate 
gravity infusions. 
296 (90.4%) 10 (2.7%)* 0 (0.0%)* 28   (6.9%) 
2. Use infusion set-up with immediate 
access to primary flush and emergency 
equipment.   
 
257 (77.2%) 
 
25 (7.5%)* 
 
7 (2.1%)* 
 
45 (13.2%) 
3. Assess and document administration 
site and its appearance. 
 
296 (88.9%) 
 
9  (2.7%)* 
 
1 (0.3%)* 
 
28   (8.1%) 
4. Assess and document treatment 
tolerance and any immediate effects. 
 
281 (84.4%) 
 
12 (3.6%)* 
 
2 (0.6%)* 
 
39 (11.4%) 
Note: Numbered variables correspond to “Treatment Administration Error Prevention” survey (See Appendix C). 
*Impact on practice is considered to have occurred if respondents selected either response option 2 or 3.  
Footnotes: Full survey response options: 
1 I consistently performed this behavior prior to course completion and no change was needed. 
2 I sometimes or mostly performed this behavior prior to course completion and am now more aware of the need to perform it. 
3 I did not perform this behavior prior to course completion and have since started performing the behavior. 
4 I did not perform this behavior prior to course completion and still do not perform it. 
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Table 4 
 
Perceived Impact on Practice:  
Organizational Policy and Procedure Error Prevention Variables (N = 334) 
Policy/Procedure (P&P) Type 
P&P already 
in place; no 
change needed1 
Started 
discussion 
about P&P 
revision2* 
P&P already 
in place; 
unsure if 
change needed3 
P&P were not 
and still not in 
place4 
Unsure if P&P 
are in place5 
Frequency (%) Frequency (%) Frequency (%) Frequency (%) Frequency (%) 
 1. P&P support and detail steps 
and components in the 
pretreatment verification process. 
159 (47.7%) 130 (39.0%)* 31   (9.1%) 7 (2.1%) 7 (2.1%) 
 2. P&P support and detail steps 
and components in the treatment 
administration process. 
172 (51.7%) 122 (36.6%)* 30   (8.7%) 4 (1.2%) 6 (1.8%) 
 3. P&P support and detail 
pretreatment and administration 
documentation requirements. 
184 (55.3%) 101 (30.3%)* 36 (10.5%) 4 (1.2%) 9 (2.7%) 
Note: Numbered variables correspond to “Organizational Error Prevention Policies and Procedures” survey (See Appendix C). 
*Impact on practice is considered to have occurred if respondents selected response option 2.  
Footnotes: Full survey response options  
1 I know effective policies and procedures were already in place prior to course completion and no change was needed. 
2 I know these policies and procedures were already in place, but I started discussions or approached peers and/or nurse leaders 
about the need to review or revise specific policies and procedures. 
3 I know these policies and procedures were already in place, but do not know if changes are needed.  
4 I know these policies and procedures were not previously in place and are still not in place. 
5 I am unsure if these policies and procedures are in place. 
 
Table 5 
Perceived Barriers to Individual Practice Change (N = 334) 
Barrier Frequency (%) 
I have not encountered any barriers to initiating change in my own practice or did not need to 
initiate change in my own practice. 
130 (38.9) 
I need to find ways to more effectively engage patients in chemotherapy error prevention. 106 (31.7) 
I believe the physician and pharmacist are responsible to verify orders to prevent chemotherapy 
errors. 
59 (17.7) 
 I have mentioned changes to other nurses but they have questioned the changes I want to make. 55 (16.5) 
I do not have enough time to make changes in my pretreatment and treatment administration 
tasks. 
39 (11.7) 
I am reluctant to change my own practice because it will be different from the practice of other 
nurses. 
23   (6.9) 
I am unsure of nursing policies and procedures in my practice setting that may help me to 
prevent chemotherapy errors. 
21   (6.3) 
I do not feel the chemotherapy educational program provided enough information about how I 
can prevent chemotherapy errors. 
19   (5.7) 
I am unsure what chemotherapy error prevention strategies for nurses are included in guidelines 
and standards. 
17   (5.1) 
I believe that using computerized order systems and electronic health records eliminates the risk 
for chemotherapy errors. 
1   (0.3) 
Note: Participants selected any and all statements that reflected their perception of challenges encountered or 
anticipated when initiating error prevention change in his/her personal practice (See Appendix C). 
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Table 6 
Perceived Barriers to Organizational Policy and Procedure Change (N=334) 
Barrier Frequency (%) 
I have not encountered any barriers to initiating change in policies and procedures or did not 
need to initiate change to policies and procedures. 
129 (38.6) 
Inadequate staffing and time constraints affect compliance with policies and procedures in my 
organization. 
102 (30.5) 
Electronic ordering and documentation systems are not easily changed or are not integrated in 
my organization. 
70 (21.0) 
Ongoing education and monitoring for the prevention of errors is lacking in my organization. 59 (17.7) 
Policies and procedures in my organization do not or may not include provide best practices for 
chemotherapy error prevention. 
54 (16.2) 
Effective interprofessional communication is lacking in my organization. 53 (15.9) 
Leaders in my organization lack understanding regarding the need for change. 50 (15.0) 
Leaders in my organization lack knowledge regarding error prevention strategies. 49 (14.7) 
Leaders in my organization are not receptive to ideas for change. 36 (10.8) 
Evidence and resources to validate the need for change in my organization are lacking. 36 (10.8) 
My organization does not prioritize chemotherapy error prevention strategies. 32   (9.6) 
The culture in my organization makes me reluctant to offer suggestions. 29   (8.7) 
Recommending additional error prevention strategies in policies and procedures may lead to a 
higher risk for punitive action if those tasks are not performed. 
22   (6.6) 
Note: Participants selected any and all statements that reflected their perception of challenges encountered or 
anticipated when initiating change to organizational policies and procedures, including documentation forms and 
quality improvement monitoring (See Appendix C).  
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Table 7 
Individual Pretreatment and Treatment Administration Error Prevention Behavior Variables by Certified 
and Non-certified Nurses (N = 331) † 
Behavior  
Certified Nurses* Non-certified 
Nurses** 
p value 
Frequency (%) Frequency (%) 
Pretreatment: Confirm planned treatment education and patient 
consent for treatment are documented: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
 134 (76.6%) 
6   (3.4%)*** 
0   (0.0%)*** 
   35 (20.0%) 
 
 
 109 (69.0%) 
16 (10.1%)*** 
4   (2.5%)*** 
   29 (18.4%) 
0.010† 
Pretreatment: Review allergies and current list of all medications 
for potential interactions: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
 126 (72.0%) 
  1   (0.6%)*** 
  2   (1.1%)*** 
   46 (26.3%) 
 
 
   105 (66.5%) 
15  (9.5%)*** 
  5  (3.2%)*** 
     33 (20.9%) 
<0.001† 
Pretreatment: Verify and document actual patient height and 
weight: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
 146 (83.9%) 
7   (4.0%)*** 
1   (0.6%)*** 
   20 (11.5%) 
 
 
109 (69.9%) 
19 (12.2%)*** 
4   (2.6%)*** 
  24 (15.4%) 
0.005† 
Pretreatment: Ensure and document order completeness by 
verifying each drug’s name, dose, volume, administration route, 
administration rate, expiration date, and physical appearance: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
 
 151 (86.8%) 
3   (1.7%)*** 
0   (0.0%)*** 
   20 (11.5%) 
 
 
 
120 (76.4%) 
13   (8.3%)*** 
3   (1.9%)*** 
   21 (13.4%) 
0.005† 
Pretreatment: Verify and document any drug-specific cumulative 
dose and dose limits: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
   84 (48.0%) 
24 (13.7%)*** 
8   (4.6%)*** 
   59 (33.7%) 
 
 
  58 (37.4%) 
39 (25.2%)*** 
19 (12.3%)*** 
   39 (25.2%) 
0.001† 
Pretreatment: Verify and document correct hazardous drug 
labeling: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
 129 (73.7%) 
3   (1.7%)*** 
7   (4.0%)*** 
   36 (20.6%) 
 
 
 110 (70.1%) 
17 (10.8%)*** 
5   (3.2%)*** 
   25 (15.9%) 
0.004† 
Pretreatment: Ensure and document that two individuals verify 
patient identification: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
 164 (93.7%) 
0   (0.0%)*** 
1   (0.6%)*** 
   10   (5.7%) 
 
 
 126 (80.3%) 
9   (5.7%)*** 
9   (5.7%)*** 
  13  (8.3%) 
<0.001† 
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Table 7 (continued) 
Behavior  
Certified Nurses* Non-certified 
Nurses** 
p value 
Frequency (%) Frequency (%) 
Treatment Administration: Assess and document administration 
site and its appearance: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
  162 (93.1%) 
0   (0.0%)*** 
0   (0.0%)*** 
   12   (6.9%) 
 
 
 133 (84.2%) 
9   (5.7%)*** 
1   (0.6%)*** 
   15   (9.5%) 
0.002† 
Treatment Administration: Assess and document treatment 
tolerance including any immediate effects: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
  160 (91.4%) 
0   (0.0%)*** 
1   (0.6%)*** 
   14   (8.0%) 
 
 
 121 (76.6%) 
12   (7.6%)*** 
1   (0.6%)*** 
   24 (15.2%) 
<0.001† 
†All p values are associated with Fisher’s Exact Test of association between the row and columns variables. Only statistically 
significant results at the 0.01 level are reported. 
*Certified nurses = Participants with reported OCN®, AOCN®, AOCNS®, AOCNP®, CBCN®, BMTCN®, CPHON® certification. 
**Non-certified nurses = No professional oncology certification reported. 
***Impact on practice is considered to have occurred if respondents selected either response option 2 or 3.  
Footnotes: Full survey response options  
1 I consistently performed this behavior prior to course completion and no change was needed. 
2 I sometimes or mostly performed this behavior prior to course completion and am now more aware of the need to perform it. 
3 I did not perform this behavior prior to course completion and have since started performing the behavior. 
4 I did not perform this behavior prior to course completion and still do not perform it. 
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Table 8 
Individual Pretreatment and Treatment Administration Error Prevention Behavior Variables by Inpatient 
and Outpatient Nurses (N = 325) † 
Behavior  
Inpatient Nurses* Outpatient Nurses** p 
value Frequency (%) Frequency (%) 
Pretreatment: Verify and document any drug-specific 
cumulative dose and dose limits: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
    52 (35.6%) 
32 (21.9%)*** 
17 (11.6%)*** 
    45 (30.8%) 
 
 
      89 (49.7%) 
28 (15.6%)*** 
9   (5.0%)*** 
       53 (29.6%) 
0.004† 
 
Treatment Administration: Use infusion set-up with immediate 
access to primary flush line and emergency equipment: 
●Consistently performed; no change needed1 
●Sometimes performed; more aware of need to perform2*** 
●Did not perform; have started performing3*** 
●Did not perform; still do not perform4 
 
 
103 (70.1%) 
17 (11.6%)*** 
4   (2.7%)*** 
23 (15.6%) 
 
 
    152 (84.0%) 
7   (3.9%)*** 
2   (1.1%)*** 
      20 (11.0%) 
0.002† 
 
†All p values are associated with Fisher’s Exact Test of association between the row and columns variables. Only statistically 
significant results at the 0.01 level are reported.  
*Inpatient nurses = Participants reporting primary chemotherapy care setting as inpatient oncology, inpatient non-oncology, 
intensive care, or bone marrow transplant. 
**Outpatient nurses = Participants reporting primary chemotherapy care setting as outpatient oncology or infusion center. 
Not included = Hospice/palliative, long-term care, home care settings due to very limited participants reporting these settings. 
***Impact on practice is considered to have occurred if respondents selected either response option 2 or 3.  
Footnotes: Full survey response options:  
1 I consistently performed this behavior prior to course completion and no change was needed. 
2 I sometimes or mostly performed this behavior prior to course completion and am now more aware of the need to perform it. 
3 I did not perform this behavior prior to course completion and have since started performing the behavior. 
4 I did not perform this behavior prior to course completion and still do not perform it. 
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Table 9 
Perceived Barriers to Individual and Organizational Change by Age and by Years  
of Nursing Practice † 
Groups of Nurses 
One or More Barriers to 
Individual Practice Change 
Identified 
One or More Barriers to 
Organizational Policy and 
Procedure Change Identified 
Frequency (%) p value Frequency (%) p value 
Age of Nurses 
20-29 Years of Age (n=60) 
30-39 Years of Age (n=91) 
40-49 Years of Age (n=79) 
> 50 Years of Age (n=103) 
 
49 (82%) 
57 (63%) 
39 (50%) 
59 (57%) 
0.001† 
 
 
47 (78%) 
59 (65%) 
46 (58%) 
53 (52%) 
0.005† 
 
Years of Nursing Practice 
< 3 Years in Nursing (n=61) 
4-14 Years in Nursing (n=131) 
> 15 Years in Nursing (n=139) 
 
46 (75%) 
83 (63%) 
72 (52%) 
0.005† 
 
 
44 (72%) 
87 (66%) 
71 (51%) 
0.005† 
 
†All p values are associated with Fisher’s Exact Test of association between the row and columns variables. Only 
statistically significant results at the 0.01 level are reported.  
Note: Participants selected any and all statements that reflected their perception of challenges encountered or 
anticipated when initiating error prevention change in his/her personal practice (See Appendix C). 
 
 
  
 
 
 
 
 
